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The immune system represents a collection of cellular elements and defensive mechanisms 
to protect the host organism from a variety of microbial pathogens. It can be divided into the 
innate and the adaptive immune system. Innate immunity is a fast response system 
comprising phagocytic cells like macrophages, dendritic cells, neutrophils as well as mast 
cells, eosinophils, basophils and natural killer cells. Cells of the innate immune system 
recognize a broad range of pathogen-associated molecular patterns (PAMPs) and initiate 
immune reactions. The adaptive immune system consists of lymphocytes (T and B cells) 
and is characterized by a slower but highly specific response and formation of an 
immunological memory. T and B cells recognize pathogens by specific receptors and upon 
activation cause their elimination. The primary tasks of the immune system are the 
maintenance of tissue homeostasis and providing a defense against pathogens throughout 
the organism. However, under certain circumstances the responses of adaptive immunity 
are directed against self-tissue, causing autoimmune diseases such as rheumatoid arthritis, 
type I diabetes or multiple sclerosis. 
 
1.1 MULTIPLE SCLEROSIS 
 
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system (Compston and Coles, 2002). Multiple sclerosis manifests as a highly heterogenic 
disease with regard to clinical symptoms, disease course, histopathology and response to 
therapies. With a prevalence of around 0.15 % in the Caucasian population, MS is the most 
common chronic progressive disorder of the CNS. Disease onset is between the age of 
20 and 50 years and the disease occurs twice as frequently in women as in men. The 
symptoms fall into a broad range: motor and sensory dysfunctions often including 
impairment of vision are the most commonly observed, but symptoms also can comprise 
cognitive disturbance, fatigue or pain. Four main forms of disease progression have been 
defined (Lublin and Reingold, 1996): relapse-remitting (RR-MS, 80 %), mostly followed by a 
secondary-progressive disease course (SP-MS, 65 % of RR-MS patients), primary-
progressive (PP-MS, 10-20 %) and progressive-relapsing (PR-MS, 10 %). 
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The etiology of MS is poorly understood. Several factors have been proposed to contribute 
to MS pathogenesis including environmental risk factors (hygiene hypothesis), genetic 
predispositions and previous pathogen infections, e.g. with the Epstein-Barr virus (Ascherio 
and Munger, 2007; Compston and Coles, 2002). 
Genetic studies revealed a number of polymorphisms in genes encoding MHC molecules 
(HLA) essential for antigen presentation and molecules involved in T cell biology such as 
IL-2R, IL-7R or CD6 (Gourraud et al., 2012) which are associated with a higher risk of MS. 
This strongly argues for the (auto)immune nature of MS. On the tissue level, the disease is 
characterized by the formation of lesions, also termed plaques, in the brain and spinal cord 
- predominately in the white matter - with the loss of myelin (demyelination) that is in many 
cases associated with axonal degeneration and gliosis. Commonly, the infiltration of 
immune cells including T lymphocytes and macrophages are found within such lesions. 
Although B cells are infrequently found within the MS-affected CNS, the presence of so 
called “oligoclonal bands” (considered as autoantibodies) in the cerebrospinal fluid of MS 
patients also suggests the involvement of humoral immunity. Therefore, in the absence of 
evidences for any involvement of pathogenic microorganisms, this picture can be 
interpreted as destructive reaction of the immune system directed against self-CNS tissue 
resulting in functional impairment (e.g. motor or sensory dysfunction, Nylander and Hafler, 
2012).  
Histopathologically, MS lesions can be classified into four demyelination patterns 
(Lucchinetti et al., 2000). Pattern I and II are characterized by the infiltration of T cells and 
macrophages clustered around small veins and venules and a sharp border between 
myelinated and demyelinated regions. The hallmark of pattern II is the evidence for local 
immunoglobulin deposition and activation of the complement system. Pattern III comprises 
distal oligodendropathy with fuzzy demarcation from normal white matter, preferential loss 
of myelin-associated glycoprotein (MAG) and signs of vasculitis all of which resembles a 
virus-associated or ischemic human CNS pathology. The rarely observed pattern IV is 
characterized by prominent degeneration of oligodendrocytes in the periplaque zone 
(Lucchinetti et al., 2000). In all four types of lesions the infiltration of immune cells is 
evident, however for the patterns III and IV the primary event triggering myelin damage may 
not be the autoimmune attack but rather exogenous (viral infection) or endogenous 
(metabolic defect in oligodendroglia) factors (Lassmann et al., 2001).  
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It has not been possible to identify a single molecule as a universal target for the 
autoimmune response in MS. Autoreactive T cells responding to myelin-derived self-
antigens such as myelin basic protein (MBP), proteolipid protein (PLP) and myelin 
oligodendrocyte glycoprotein (MOG) as well as oligodendrocyte-specific proteins like 
transaldolase and -crystalline (Nylander and Hafler, 2012) are present in the immune 
repertoires of both healthy individuals and MS patients (Schmidt, 1999). For many of those 
specificities, such as the one toward MBP, increased numbers of activated T cells were 
reported in MS patients. Some candidate antigens (expressed on the cell membrane) 
causing B cell responses and production of autoantibodies have been identified. For 
instance, in neuromyelitis optica (NMO), an inflammatory and demyelinating disease 
affecting mainly the optic nerve but also the spinal cord, an antibody response is directed 
against aquaporin-4 (AQP4). Markedly, in NMO lesions a profound loss of AQP4+ 
astrocytes could be observed (Brück et al., 2012). In MS, autoantibody response to the 
potassium channel KIR4.1 was found in 47 % of patients (Srivastava et al., 2012). Whether 
a T cell response to AQP4 and KIR4.1 also occurs in the context of MS still remains to be 
determined.  
Finally, one of the most convincing arguments in favor of an (auto)immune pathogenesis of 
MS is the fact that current therapies demonstrating efficacy in MS patients target primarily, 
if not exclusively, the immune system (Table 1.1).  
 
Table 1.1: Therapeutic compounds applied for MS treatment targeting the immune system. 
Mechanism Treatment 
Inhibition of proliferation Mitoxantron, Azathioprine, Teriflunomide, Daclizumab (mAb to CD25) 
Hormonal immunosuppression Dexamethasone (Glucocorticoids) 
T cell depletion Alemtuzumab (mAb to CD52) 
Block of T cell migration Natalizumab (mAb to VLA4), Fingolimod (antagonist of S1P receptors) 
Immunomodulation Interferon-beta, Laquinimod, Copaxone (Glatiramer acetate) 
B-cell depletion Rituximab (mAb to CD20) 
  
Collectively, many of the above described features suggest that a T cell mediated 
autoimmune reaction is a mainstay of human MS pathogenesis and that a better 
understanding of how immune cells operate during neuroinflammation would contribute to 





1.2 CENTRAL NERVOUS SYSTEM – AN IMMUNE PRIVILEGED ORGAN 
 
The CNS has a particular relationship to the immune system termed as immune privilege. 
Immune privilege is characterized by the lower magnitude and higher activation threshold 
for the adaptive immune response. Experimentally, the immune privilege of the CNS was 
first demonstrated in a study of allograft rejection using transplantation of mouse skin grafts 
into the brain or periphery (MEDAWAR, 1948). This special state of the CNS evolved to 
provide a balance between the need on the one hand for immune-mediated protection 
against viral, bacterial and fungal infections and neoplastic transformation taking place 
within the CNS and on the other hand the danger of irreversible and fatal immune-mediate 
damage to the CNS. The latter is highly relevant for the brain as it is constrained by bones, 
populated by terminally differentiated neurons unable to self-renew mitotically and 
extremely vulnerable to stress (e.g. hypoxia, free radicals, toxins etc.) and contains 
structures controlling vital physiologic functions such as blood circulation and respiration. 
Under these circumstances excessive inflammatory reactions are inevitably associated with 
collateral tissue damage and represent a great threat for the survival of an organism.  
The immune privileged status of the CNS is maintained by several mechanisms. First, in 
contrast to many other organs such as skin, lung or gut, the CNS lacks an afferent 
lymphatic system. If passive traffic of soluble CNS antigens or their active carriage by 
migrating antigen-presenting cells (APCs) toward lymphoid organs occurs at all, this is likely 
to happen at the sites where the cerebrospinal fluid (CSF) can get in contact with tissues 
drained by lymphatic vessels. For instance, the CSF circulating around olfactorial nerves 
can reach the mucosa of the nasal cavity and from there enter the draining cervical lymph 
nodes. Second, CNS tissue is separated from blood circulation by the blood-brain barrier 
(BBB). Highly specialized endothelial cells are joined by tight junctions effectively 
preventing free entry of molecules and cells into the CNS. The brain endothelium lacks 
fenestration and expresses very low levels of adhesion molecules, such as ICAM-1, used 
by leukocytes to extravasate. Together with a few pericytes, the BBB endothelium is 
covered by a basement membrane, limiting perivascular space from the side of blood 
circulation. From the side of the CNS parenchyma, processes of astrocytes called endfeet 
form a continuous layer of glia limitans covered by another thin membrane. Residing within 
the perivascular space, perivascular phagocytes can be found (also called perivascular 
macrophages), fibroblast-like cells producing the extracellular matrix, collagen fibers and 
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the cerebrospinal fluid. Also, the processes of microglia cells extended from the 
parenchyma end up in the perivascular space (Engelhardt and Sorokin, 2009; Engelhardt 
and Ransohoff, 2005). Third, CNS tissue per se represents an immunohostile environment. 
This property refers to the negligible expression of immune factors such as MHC molecules 
and proinflammatory cytokines and chemokines in the healthy CNS.  
The former view that the CNS is sequestered from the peripheral immune system (Barker 
and Billingham, 1977) has changed. In histological analysis of healthy humans or rodents, 
T cells could be detected at very low frequencies in perivascular, subarachnoid or 
meningeal spaces indicating the CNS being a target for constant immune surveillance (Deli 
et al., 2005). As these cells are not activated, they do not further penetrate the CNS tissue 
and do not accumulate locally. This rapidly changes however when innate immune cells 
become activated, e.g. in case of viral/bacterial infection or stroke, resulting in a massive 
influx of myeloid cells and T lymphocytes from circulation. 
A variety of questions dealing with immune privilege and immune surveillance of the CNS 
arise in the context of MS: How is central and peripheral tolerance of myelin-reactive T cells 
towards self-CNS tissue maintained? How do CNS derived antigens become presented to 
T cells outside and within the CNS and what is the role of subtypes of antigen presenting 
cells (APCs)?  Which properties of T cells allow transmigration of the BBB and the entry 
into the CNS parenchyma and which of them can be therapeutically targeted in MS 
patients? What subsets of T cells are crucial for the initiation, progression and resolution of 
neuroinflammation? What is the interplay between inflammation and degeneration of CNS 
tissue (e.g. demyelination and axonal damage) and subsequent repair? Many of these 
questions cannot be answered efficiently without the aid of animal models.  
1.3 EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS  
 
The heterogeneity of MS, the limited amount of patient-derived material available for 
analysis and ethical constrains substantially complicate research of MS. Therefore, 
understanding molecular mechanisms of neuroinflammation and development of new 
therapeutic options require experimental modeling of human pathology in animals. No 
spontaneous MS-like disease has been reported in commonly used laboratory species. A 
demyelinating CNS pathology can be induced in rodents by infection with certain viruses 
(e.g. Theiler’s murine encephalomyelitis virus, Miller et al., 1997) or by toxic damage of 
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oligodendroglia (cuprizone in mice, lysolecitin in rats, Blakemore, 1973; Mitchell and Caren, 
1982). However, the classical animal model to mimic MS-like symptoms in order to study 
autoimmune processes in the CNS is experimental autoimmune encephalomyelitis, EAE 
('t Hart et al., 2011). Active EAE can be induced by the immunization of animals (that is 
injection of antigen in combination with adjuvant) with components of the myelin sheath 
(Fig. 1.1) in a variety of species, e.g. in primates (Rivers et al., 1933), dogs (THOMAS et 
al., 1950), rats (LIPTON and FREUND, 1952) or mice (OLITSKY and YAGER, 1949). 
Passive EAE can be induced by the adoptive transfer of myelin-specific T cells in mice and 


















Figure 1.1: CNS autoantigens implicated in MS or experimental autoimmunity. ODC, oligodendrocyte. MOG, myelin 
oligodendrocyte glycoprotein. MAG, myelin-associated glycoprotein. MBP, myelin basic protein. PLP, proteolipid protein. NF-M, 
medium-sized neurofilament. S100, S100 calcium binding protein B. AQP4, aquaporin 4. KIR4.1, potassium channel. APC, 
antigen-presenting cell.     
 
The genetic background of rodent strains and the nature of antigens used for immunization 
determine the pathology and the disease course (Examples see Tab. 1.2 and Fig. 1.2).  
Widely used active mouse EAE models are the MOG35-55-induced chronic paralytic disease 
in the C57BL/6 strain and the PLP139-151-induced relapsing-remitting EAE in the SJL/J 
strain. The use of adjuvants for the induction of EAE and the fact that inflammatory 
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infiltrates in the EAE-affected CNS tissue dominate over signs of demyelination distinguish 
the model from human MS disease. Also, an inbred (homogeneous) genetic background of 
mice and their housing under conditions devoid of a natural microbial environment make a 
profound distinction to human autoimmunity. However, the ability to manipulate individual 
cell types and processes by genetic and/or pharmacologic means places rodent EAE as 
valuable and highly demanded tool in the field of neuroimmunological research. 
 
Table 1.2: Myelin antigens used for induction of EAE in different species. 
Species/strain Autoantigen Disease course 
Mouse – C57N/BL6 MOG Chronic (Mendel et al., 1995) 
Mouse – SJL/J PLP Relapsing-Remitting (Tuohy et al., 1988) 
Mouse – C3HeB/Fej MOG  Atypical EAE course (Stromnes et al., 2008) 
Rat – Lewis rat MBP Monophasic (LIPTON and FREUND, 1952; LIPTON and FREUND, 1953) 
Rat – Lewis rat Spinal cord homogenate Monophasic (Wekerle and Sun, 2010) 
Rat – Brown Norway MOG Neuromyelitis optica (Weissert et al., 1998) 
Rat – Brown Norway Spinal cord homogenate Monophasic (Wekerle and Sun, 2010) 
Rat – Dark Agouti MBP Monophasic (Momcilovic et al., 2008; Stosic-Grujicic et al., 2004) 
Rat – Dark Agouti Spinal cord homogenate Chronic-relapsing EAE (Wekerle and Sun, 2010) 
Marmosets MOG Relapsing-Remitting (Kap et al., 2008; Jagessar et al., 2010) 
 
 
1.3.1 ACTIVE EAE IN LEWIS RATS 
In Lewis rats, EAE manifests as an acute monophasic paralytic disease (Fig. 1.2). It can be 
actively induced via immunization of naïve rats with myelin basic protein emulsified in 
complete Freund’s adjuvant (CFA). Ten days after active immunization, Lewis rats develop 
EAE accompanied by loss of body weight and starting with a paresis of the tail and 
ascending to a complete paralysis of the hind limbs. Remarkably, the disease course is 
monophasic and animals recover completely. The development of clinical symptoms is 
accompanied by perivascular infiltration of T cells and macrophages (Huitinga et al., 1995) 
detected primarily in the spinal cord. Lewis rats challenged with a second MBP 
immunization did not develop a second disease bout (Sun et al., 1999).  The reason for this 
resistance could be an induction of regulatory T cells (Tregs). Interestingly, low-dose 
treatment of Lewis rats with cyclosporine A, that presumably affects predominately Treg 
cells which are strongly dependent on IL-2, did not prevent EAE but converted the disease 
course to a chronic/relapsing form (Polman et al., 1988). Furthermore, Lewis rat EAE is a 
8 
 
useful model to investigate new therapeutic drugs, e.g. anti-VLA-4 mAb (Yednock et al., 
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Figure 1.2: Types of disease course in EAE models 
 
1.3.2 ADOPTIVE TRANSFER EAE IN LEWIS RATS 
EAE in Lewis rats can be induced via the adoptive transfer of MBP-specific CD4+ effector 
T cells activated ex vivo (Ben-Nun et al., 1981). The disease course is again monophasic 
starting with a paresis of the tail and ascending to a complete hind limb paralysis. 
Afterwards, the animals recover completely.  
Transfer EAE convincingly proved the crucial role for myelin-specific T cells in EAE 
development. Transfer EAE is a potent model to study the behaviour and function of 
pathogenic T cells in vivo. One advantage of using the adoptive transfer of myelin specific 
T cells to evoke EAE is the possibility to genetically engineer these T cells to express 
fluorescent markers or other genes using ex vivo T cell culture (Flügel et al., 1999). Using 
GFP-tagged TMBP lines the migratory route of the transferred pathogenic T cells can be 
followed in vivo and the migratory behavior outside and within the CNS can be visualized 
using two-photon live microscopy (Bartholomäus et al., 2009).  
Remarkably, recipient rats do not develop EAE directly after T cell transfer but only after a 
prodromal phase of about 3 days (Wekerle et al., 1994). Within this period, the transferred 
T cells are largely absent in the circulation and home preferentially into the spleen and the 
lung (Odoardi et al., 2012). The observation that adoptively transferred T cell blasts do not 
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attack the CNS directly after transfer was explained until recently by a T cell hostile milieu 
of the CNS and the integrity of the blood-brain barrier (Greter et al., 2005). To evoke 
inflammation and the development of paralysis, T cells were thought to infiltrate the CNS in 
two distinct waves: First, a few pioneer T cells were believed to transmigrate the blood-
brain barrier and become reactivated within the CNS thereby causing an inflammatory 
milieu and BBB damage. Then, a second wave of myelin specific T cells was thought to 
enter the CNS causing the clinical symptoms (Odoardi et al., 2007; Wekerle et al., 1986). 
Recently, Odoardi et al. could demonstrate that transferred T cells home into peripheral 
milieus like lung and spleen during the prodromal phase. There, the T cells acquire a 
migratory phenotype by down-regulating inflammatory factors (IFN, TNF) and up-
regulating adhesion molecules (LFA-1, VLA-4, Ninjurin1) and chemokine receptors 
(CXCR3, CXCR4, S1P1). As T cells isolated from spleens of rats in the preclinical phase of 
atEAE induce disease much faster than freshly activated blast do upon retransfer in naïve 
animals, the phenotype acquired in peripheral organs seems to enable the T cells to 
efficiently cross an apparently intact blood-brain barrier and get reactivated by local antigen 
presenting cells within the CNS causing EAE (Odoardi et al., 2012). 
 
1.3.3 TCR TRANSGENIC MOUSE MODELS FOR STUDYING CNS AUTOIMMUNITY 
Studying autoimmunity in the mouse is greatly facilitated by using transgenic mouse strains 
with a myelin-specific T cell receptor (as well as B cell receptor). In these mice, nearly all T 
cells of the immune repertoire express the transgenic T cell receptor (TCRtg) with a defined 
specificity for a given autoantigen. Therefore TCRtg mice can be used to analyse 
autoantigen specific T cells in immune reactions both in vitro and in vivo. Additionally, some 
of the TCRtg mouse lines do also develop EAE spontaneously and can be used to 
investigate the initial T cell activation causing the disease.  
Until now, there is a broad range of TCR transgenic mouse strains available with different 
EAE initiation and progression patterns (Tab. 1.3). 
The first myelin specific TCR transgenic mouse lines were described by Goverman et al. 
(1993) expressing a MHCII-restricted TCR specific for MBP. In these mice, EAE could be 
induced via active immunization with an earlier disease onset and stronger disease 
phenotype. The disease could even be evoked by administration of non-specific immune 
stimuli like CFA or lipopolysaccharide (LPS). Interestingly, when kept under specific 
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pathogen-free conditions instead of germ-free housing, some individuals of this mouse line 
developed EAE spontaneously. 
Additionally, the MHCII-restricted MBP-specific TCR transgenic mouse line developed by 
Lafaille et al. (1994) displayed a spontaneous EAE incidence of around 14 %. This could be 
increased to 100 % by crossing these mice to the RAG1-knockout background. These mice 
then lack all B cells and non-transgenic T cells.  
In 2003, Bettelli et al. reported the first MHCII-restricted MOG-specific TCR transgenic mice 
(2D2 mice). Here, the TCR recognized the MOG peptide 35-55 and the mice developed 
spontaneous paralytic EAE to a very low degree. However, around 30 % of the mice 
spontaneously developed optic neuritis.  
The 2D2 mice were then crossed with IgHMOG mice (Litzenburger et al., 1998), which 
express the heavy chain of the MOG specific demyelinating antibody 8.18c5 instead of the 
endogenous JH sequence. In these double-transgenic mice expressing both MOG-specific 
T cells and antibodies, the disease incidence was increased to 50-60 % with an earlier 
disease onset and a stronger disease phenotype compared to 2D2 mice (Bettelli et al., 
2006; Krishnamoorthy et al., 2006).  
Mice expressing a MOG-specific TCR for the peptide 92-106 on the SJL/J background 
developed spontaneous EAE with a relapse-remitting phenotype with an even stronger 
manifestation of demyelination when additionally crossed with the IgHMOG mice (Pollinger et 
al., 2009). 
In multiple sclerosis patients, it was demonstrated that not only CD4+ T cells play a role in 
neuroinflammatory processes but also that myelin-specific CD8+ T cells can be found in 
CNS lesions and the cerebrospinal fluid (Babbe et al., 2000). Also, myelin-specific CD8+ 
T cells can induce axonal loss via “collateral bystander damage” (Sobottka et al., 2009). To 
further characterize the role of myelin-specific CD8+ T cells in immune responses, the 
Goverman lab introduced a MHC-I restricted MBP-specific TCR transgenic mouse strain 
(Huseby et al., 2001a). 
Along this line, transgenic mice were created expressing ovalbumin under the control of the 
MBP promoter driving expression in oligodendrocytes (ODC-OVA). In these mice, unless 
actively immunized, CD4+ T cells and B cells remain ignorant of the antigen (Cao et al., 
2006). This observation could also be confirmed in animals expressing a MHC class II 
restricted OVA-specific TCR (Barnden et al., 1998) as CD4+ T cells did not recognize 
ovalbumin expressed by oligodendrocytes (Na et al., 2008). However, when ODC-OVA 
mice were crossed to the OT-I transgenic line (MHC class I restricted OVA-specific TCR, 
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Hogquist et al., 1994)) mice spontaneously developed lethal demyelinating EAE with 
lesions in cerebellum, optic nerve and spinal cord (Na et al., 2008). Of interest, in single 
transgenic ODC-OVA mice OVA-reactive CD8+ T cells were shown to be actively removed 
from the immune repertoire by a mechanism which could not be entirely elucidated (Na et 
al., 2012). 
Table 1.3: Overview of TCR-transgenic mouse strains used in neuroimmunology  
Strain Background Autoantigen Restriction TCR Onset Reference 





(Goverman et al., 1993) 
19 C57N/BL6 MBPAc1-9 MHCII 
V4 
V8.2 
100 % (RAG1 KO) (Lafaille et al., 1994) 
 B10.PL MBP121-150 MHCI 
V2  
V4 
0 % (Huseby et al., 2001b) 
Ob.1A12 C57N/BL6 MBP84-120 HLADR2 
V3  
V2.1 
100 % (RAG1 KO) (Madsen et al., 1999) 
2D2 C57N/BL6 MOG35-55 MHCII 
V3.2 
V11 
4 % EAE 
30 % Optic Neuritis 






C57N/BL6 MOG35-55 MHCII 
V3.2 
V11 
50 % EAE 
(Bettelli et al., 2006; Krishnamoorthy 
et al., 2006) 





(Pollinger et al., 2009) 





(Waldner et al., 2000) 
OT-I x 
ODC-OVA 
C57N/BL6 OVA257-262 MHCI 
V2 
V5 
none (Hogquist et al., 1994) 
OT-II x 
ODC-OVA 
C57N/BL6 OVA323-339 MHCII 
V2 
V5 
none (Barnden et al., 1998) 





















1.4 STRUCTURE AND DIVERSITY OF T CELL RECEPTORS 
 
T cells recognize antigenic determinants via the surface-expressed T cell receptor, TCR. 
Structurally, a T cell receptor consists of a chain and chain linked to each other via 
disulfide bridges and can recognize antigenic peptides bound to a MHC complex. The - 
and - chains can be further divided into a constant region, identical for all T cells, and a 
variable region, determining specificity. The TCR is expressed on the cell surface as a 
complex with CD3 subunits (-, -, two  chains and two  polypeptide chains) which are 
also important for signal transduction (Wucherpfennig et al., 2010).  
As the encoding of all antigenic receptors necessary to confer sufficient protection of the 
host by individual genes would require too much of genomic capacity, a mechanism called 
somatic recombination or V(D)J recombination has evolved. V(D)J recombination generates 
a highly diverse repertoire of BCRs and TCRs (Schatz and Swanson, 2011). TCR genes 
are organized as an array of V(ariable), D(iversity) and J(unction) segments, one constant 
region for the  chain and two constant regions for the  chain genes each preceded by a 
D-J cluster (Krangel, 2009). During T cell development in the thymus, these segments are 
rearranged with each other via site specific recombination resulting in deletion of 
intervening sequences (Fig. 1.3). At the same time few non-templated nucleotides can be 





































































Vβ1 Vβ2 Vβ3 Vβn Cβ1Jβ1.1-n Cβ2Dβ1 Dβ2 Jβ2.1-n
 
Figure 1.3: Structure of the TCR complex and the down-stream signaling. TCR - and -chains are assembled by 
recombination of V(ariable), D(iversity), J(unction) and splicing to C(onstant) chain regions. The rearranged TCR forms a 
complex with CD3 subunits and is transported to the cell surface enabling its interaction with antigen presented in the context 
of MHC presentation. TCR binding to peptide-MHC triggers down-stream signaling pathways resulting in activation of 
transcription factors (e.g. Nuclear Factor 'kappa-light-chain-enhancer' of activated B-cells or Nuclear Factor of Activated 
T cells) driving T cell differentiation, proliferation and cytokine production.  
 
During thymic development of T cells (at the CD4-CD8- stage), the genomic D segment 
of the -chain is first fused to one of the J segments and then to one of the upstream 
Vß segments (Krangel, 2009). The leader sequence and exons of the constant region are 
combined with the VDJ exon during splicing of a primary RNA transcript. Later, at the 
CD4+CD8+ double-positive stage, V and J undergo rearrangement. Due to these 
rearrangements of numerous gene segments (e.g. >20 V and >70 V), the combinatorial 
diversity of a T cell receptor repertoire can be around 1016 (Tonegawa, 1983; Davis and 
Bjorkman, 1988). The diversity of peripheral T cells with completed thymic development 
was estimated to be around 107 (Arstila et al., 1999). This reduction is due to selection 
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processes taking place within the thymus. Functionality of the TCR is tested during the 
development first in a process called  selection, and subsequently by positive and 
negative selection.  
For -selection, the chain is expressed together with a pre-T invariant chain to test 
structural properties that permit the expression of the pre-T-TCR pair in complex with 
CD3 on the cell surface. Those thymocytes that passed the -selection checkpoint, 
temporally shut down V(D)J-recombination, proliferate and transit to the CD4+CD8+ stage. 
There, the  chain is rearranged, translated and expressed as TCR:CD3 complex. 
During positive selection, the interaction of the TCR with a MHC molecule is tested 
leading to the deletion of T cells expressing a TCR unable to bind to MHC molecules. 
Lastly, during negative selection, the TCR interaction to self-peptides is tested and TCRs 
recognizing self-peptides expressed in the thymus are deleted from the repertoire 
(BURNET, 1959; Kappler et al., 1987). After passing positive and negative selection, T cells 
down-regulate the expression of one of the coreceptors resulting in either CD4 or CD8 
single-positive T cells depending on whether the TCR interacted with a MHC class I or 
MHC class II molecule (Teh et al., 1988).  
 
1.5 T CELL RECEPTOR SIGNALING 
 
After thymocyte development, functional T cells leave the thymus and recirculate in the 
periphery. Naïve T cells become activated when antigen loaded APCs meet them in lymph 
nodes or spleen (Fig. 1.3). Upon antigen recognition via TCR:CD3/pMHC interaction, an 
immunological synapse is formed bringing the TCR:CD3 complexes in close proximity to 
CD45 and the coreceptor molecule. Intracellular domains of the CD3 subunits contain 
ITAMs (immunoreceptor tyrosine-based activation motif) and both the TCR:CD3 complex 
as well as the coreceptor are associated with the tyrosine kinases Fyn and Lck. Close 
proximity of the tyrosine phosphatase CD45 enables the dephosphorylation of Fyn and Lck 
leading to the subsequent phosphorylation of CD3 chains. This enables the association 
and activation of ZAP-70 (-associated protein 70) resulting in the activation of many 
downstream targets. One of them, phospholipase C- (PLC) cleaves phosphatidylinositol-
biphosphate into diacylglycerine (DAG) and inositoltriphosphate (IP3). DAG activates a 
transduction pathway leading to the activation of protein kinase C and the transcription 
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factor NFkB whereas IP3 leads to depletion of intracellular calcium stores driving influx of 
extracellular calcium that in turn mediates nuclear translocation of the transcription factor 
NFAT (nuclear factor of activated T cells). Both transcription factors enable the gene 
transcription of factors driving T cell proliferation and the production of cytokines 
(IFNTNFIL-2, IL-4, IL-17 and others, Brownlie and Zamoyska, 2013).  
 
1.6 TRANSGENIC APPROACHES 
 
In mice, TCR transgenic animals have been obtained via pronuclear injection of DNA 
expression constructs shuttling rearranged TCR sequences into oocytes. Although these 
constructs are randomly integrated into the host genome, they can be engineered to 
contain regulatory elements, such as promoters and enhancers driving expression in T cells 
(e.g. Kouskoff et al., 1995) in a developmentally controlled manner. Classically, the 
generation of transgenic rats was also achieved by pronuclear DNA injection (Mullins and 
Mullins, 1996) but this is a technically challenging and costly process. The use of self-
inactivating lentiviruses became an alternative to generate transgenic mice and rats (Lois et 
al., 2002). In Lewis rats, this method was successfully used to create a number of 
transgenic strains, with such properties as ubiquitously expressed GFP and conditional 
knock-down of an insulin receptor (van den Brandt et al., 2004; Herold et al., 2008). A 
limitation of using the lentiviral approach is the restricted capacity of the viral genome, 
precluding integration of all necessary regulatory elements in addition to the sequence of 
two TCR chains. Von Holst et al. reported the generation of TCR transgenic chimeric mice 
by retroviral transduction of bone-marrow and transfer to irradiated hosts (Holst et al., 
2006). In this retrogenic approach, surface expression of a transgenic TCR encoded by 
integrated provirus occurs only in cells committed to CD3 expression. Retrogenic mice do 
not transmit TCR expression to the next generation and have to be produced anew for 
multiple experiments. However, these studies imply that germline competent lentiviral 
vectors equipped with multicistronic cassettes can be used in rats to confer stable 
expression of TCRs with predetermined specificity to mature T cells in vivo.   
Recently, conditions were defined for establishing and propagating germ-line competent rat 
ES cells (Li et al., 2008). This breakthrough enabled the generation of mutant rats by gene 
targeting using homologous recombination in ES culture, e.g. generating a p53 knock-out 
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strain (Tong et al., 2011) and establishing knock-in strains expressing GFP (Blair et al., 
2012) or tdTomato (Kobayashi et al., 2012). Additionally, new methods for generation of 
“loss-of-function” mutants were introduced into the rat genetic toolset e.g. utilizing TALEN-, 
Cas9-, or zinc finger nuclease-mediated targeting (Carroll, 2011; Shen et al., 2013; Zhang 
et al., 2011; Geurts et al., 2009). The latter method was successfully applied for the 
generation of Rag1 knock-out rats (Zschemisch et al., 2012). As the amount of knock-out 
rat strains will increase within the next years, the generation of TCR transgenic Lewis rats 
will provide a useful tool for immunological studies. 
 
1.7 AIMS OF THE STUDY 
 
Rodent EAE represents a central model for studying autoimmunity in the CNS and 
delineating putative therapeutic targets for MS treatment. Lewis rat adoptive transfer EAE 
has proven to be extremely useful in learning about the migration of effector CD4 T cells 
through the body and specifically at the BBB during an autoimmune attack. It is particularly 
well suited for intravital microscopy studies (Bartholomaus et al., 2009; Odoardi et al., 2012; 
Lodygin et al., 2013).  
However, several limitations also exist, namely that pathogenic naïve T cells are not 
accessible, the onset of EAE is not spontaneous, and that no chronic or relapsing disease 
can be studied. Also, this model is biased toward a CD4+ Th1-driven response due to the 
used adjuvant. Lessons from TCR transgenic mice suggest that some of these limitations 
can be overcome by generating a transgenic rat strain in which the majority of T cells 
express a TCR specific for CNS autoantigens.  
 
During this project we therefore pursue two aims: 
1. Generation and characterization of TCR transgenic Lewis rats carrying T cell 
receptors specific for the myelin basic protein (i) and the non-self model antigen 
ovalbumin (ii). 
2. Analysis of migratory routes, T cell phenotypes and pathogenesis of EAE induced 
by in vivo primed T cells. 
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2. MATERIALS AND METHODS 
2.1 BUFFERS AND MEDIA 
 
Table 2.1: Basic buffer and media compositions 
Buffer Composition* Used for 
10x PBS 
80 mM Na2HPO4 
1.5 M NaCl 
20 mM KH2PO4 
30 mM KCl 
pH 7.4 
Isopercoll 
1x PBS 10 x PBS diluted in A. dest Basic buffer 
10x TBE 
1 M Tris 
0.9 M boric acid 
0.01 M EDTA 
 
1x TBE 10 x TBE diluted in A. dest Gel electrophoresis 
AcK Buffer 
0.15 M NH4Cl 
10 mM KHCO3 
0.1 mM EDTA 
Lysis of Erythrocytes 
FACS Buffer 
0.5 % BSA (Code # BSA-10) 
0.05 % Natrium acide 
in PBS 
FACS stainings 
LB Medium 25 g/l Luria/Miller LB medium Culturing of bacteria 
LB Agar 
1 % tryptone 
0.5 % yeast extract 
10 mM NaCl 
1.5 % agar 
Culturing of bacteria 
SOC Medium 
2 % tryptone 
0.5 % yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
Transformation of bacteria 
 





2.2 MOLECULAR PROCEDURES 
2.2.1 RNA EXTRACTION AND COMPLEMENTARY DNA SYNTHESIS 
RNA was isolated from cell suspensions or organs using the RNeasy Kit (Qiagen, Hilden, 
Germany) and transcribed into cDNA using random hexamer primers (FirstStrand cDNA 
Synthesis Kit, Thermo Fischer Scientific Inc., Waltham, US) as recommended by the 
manufacturer.  
cDNA samples were either stored at -20°C or directly used as templates for PCR reactions. 
 
2.2.2 POLYMERASE CHAIN REACTION (PCR) 
For generation of lentiviral or retroviral expression constructs, genes of interest, e.g. TCR 
receptor alpha and beta chains, were amplified by PCR from rat cDNA isolated from clonal 
cell lines. Briefly, 10 l of 2 x DreamTaq Polymerase Mix (Thermo Fischer Scientific Inc., 
Waltham, US) and 1 l of forward and 1 l of reverse primer at a concentration of 10 M 
(See Tab 2.4, Biomers, Ulm, Germany) were mixed with 7 l cDNA and incubated using the 
following PCR programme (Tab. 2.2, Eppendorf Mastercycler EP, Hamburg, Germany): 
Table 2.2: Standard PCR programme for amplification of rat TCR cDNA 
 Step Temperature Time 











 Final elongation 72°C 5 min 
 
PCR products were loaded to 0.8 % agarose gels and electrophoresed at 100 V for 30-
45 min. For molecular cloning, DNA fragments were excised from the gel using a one-way 
scalpel (BBraun Melsungen AG, Sempach, Switzerland). 
 
2.2.3 QUANTITATIVE REAL TIME PCR 
Analysis of gene expression was achieved by semi-quantitative real time PCR (qPCR) 
using the StepOnePlus Real Time PCR System (Applied Biosystems, Darmstadt, Germany) 
and the corresponding StepOne Software v2.0.  
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Beta-actin was used as a housekeeping gene. Custom designed qPCR primers and probes 
(Tab. 2.3) were ordered from Sigma Aldrich (Munich, Germany) with FAM-TAMRA as 
fluorophore-quencher pairs.  
Single strand cDNA was diluted 1:50 and 7.5 l were mixed with 12.5 l ready-to-use RT-
PCR mix (including dNTPS/dUTPs, HotGoldStar DNA polymerase, 5 mM final MgCl2 
concentration; Eurogentec, Seraing, Belgium) and 5 l of Primer-Probe mixtures and 
transferred into one well of a 96-well qPCR plate (Sarstedt AG & Co, Nümbrecht, 
Germany).  
 
Table 2.3: Primer and probe sequences for quantitative real time PCR 
Gene Oligonucleotide sequences 
 actin 
Fw: 5’-GTA CAA CCT CCT TGC AGC TCC T -3’  
Rev: 5’-TTG TCG ACG ACG AGC GC -3’   
Probe: 5’-Fam-CGC CAC CAG TTC GCC ATG GAT -Tamra-3’  
IFN 
Fw: 5’-AAC AGT AAA GCA AAA AAG GAT GCA TT -3’  
Rev: 5’-TTC ATT GAC AGC TTT GTG CTG G -3’  
Probe: 5’-Fam-CGC CAA GTT CGA GGT GAA CAA CCC -Tamra-3’  
IL-2 
Fw: 5’-CTC CCC ATG ATG CTC ACG TT-3’ 
Rev: 5’-TCA TTT TCC AGG CAC TGA AGA TG-3’ 
Probe: 5’-Fam-CAA TTC TGT GGC CTG CTT GG -Tamra-3’ 
IL-4 
Fw: 5’- CGG TGA ACT GAG GAA ACT CTG TAG A-3’ 
Rev: 5’-TCA GTG TTG TGA GCG TGG ACTC-3’ 
Probe: 5’-Fam-CGG TCT GAA CTC ACT GAG AAG CTG CAAC -Tamra-3’ 
IL-10 
Fw: 5’-GAA GAC CCT CTG GAT ACA GCT GC-3’ 
Rev: 5’-TGC TCC ACT GCC TTG CTT TT-3’ 
Probe: 5’-Fam-CGC TGT CAT CGA TTT CTC CCC TGT GA -Tamra-3’ 
IL-17 
Fw: 5’-GAG TCC CCG GAG AAT TCC AT -3’  
Rev: 5’-GAG TAC CGC TGC CTT CAC TGT -3’ 
Probe: 5’-Fam-ATG TGC CTG ATG CTG TT -Tamra-3’ 
TNF 
Fw: 5’-TCG AGT GAC AAG CCC GTA GC-3’ 
Rev: 5’-CTC AGC CAC TCC AGC TCC TC -3’  
Probe: 5’-Fam-CGT CGT AGC AAA CCA CCA AGC AGA -Tamra-3’ 
CCR2 
Fw: 5’-CAC TTA GAG CAG GCC ATG CA-3’ 
Rev: 5’-GGA GAG ATA CCT TCG GAA CTTC  -3’  
Probe: 5’-Fam-TGA CAG AGA CTC TTG GAA TGA CAC ACT GCTG -Tamra-3’ 
CCR5 
Fw: 5’-GTT CTC CTG TGG ACC GGG TAT AG -3’  
Rev: 5’- ATT GTC AAA CGC TTC TGC AAA C -3’  
Probe: 5’-Fam-AGC TTA CAC GAT CAG GAT TGA CTT GC - Tamra-3’  
CCR7 
Fw: 5’- GTG TAG TCC ACG GTG GTG TTC TC-3’  
Rev: 5’- CTG GTC ATT TCC AGG TGT GCT -3’  
Probe: 5’-Fam-CCG ATG TAG TCG TCT GTG A -Tamra-3’   
CXCR3 
Fw: 5’- AGC AGC CAA GCC ATG TAC CTT -3’  
Rev: 5’- TAG GGA GAT GTG CTG TTT TCC A -3’  




2.2.4 CLONING OF PCR PRODUCTS  
DNA fragments were extracted from agarose gels using the GeneJet Gel Extraction Kit 
(Thermo Fischer Scientific Inc., Waltham, US) according to the manufacturer’s instructions. 
Eluted PCR fragments were either introduced into pJet1.2 shuttle vector by blunt-end 
ligation (CloneJet PCR Cloning Kit, Thermo Fischer Scientific Inc., Waltham, US) or into 
pCR4 shuttle vector (TOPO-Ta-Cloning kit, Invitrogen, Carlsbad, CA, US) following the 
manufacturer’s instructions.  
The ligation or pJet1.2/TOPO-reaction mixes were transformed into chemically competent 
DH5 E. coli followed by ampicillin selection. 
 
2.2.5 PREPARATION AND DIGEST OF PLASMID DNA  
Bacterial colonies were picked from agarose plates and inoculated into ampicillin-containing 
LB-medium at 37°C and cultured overnight with shaking.  
According to the manufacturer’s instructions plasmid DNA was isolated using GeneJet 
Plasmid Miniprep Kit (Thermo Fischer Scientific Inc., Waltham, US)  
Identity of cloned fragments was confirmed by restriction analyses and DNA sequencing 
(performed at SeqLab, Göttingen, Germany). For digestion, plasmid DNA was incubated 
with FastDigest enzymes in FastDigest Buffer (Thermo Fischer Scientific Inc., Waltham, 
US) and analyzed via agarose gel electrophoresis. 
 
2.2.6 CLONING OF T CELL RECEPTOR CONSTRUCTS 
T cell receptor sequences specific for myelin basic protein or chicken ovalbumin were 
obtained from monoclonal T cell clones. Cloning strategies are described in detail in 





Table 2.4: Primer sequences for TCR cloning 
Primer Sequence Source 
 Primers for gene families of rat V segments   
RV1 AAGAAGGCAGATTCACATCA 
















    
 TCR C-region primers  
RTAC1 ATGGGCCCGCAATGGCCCCGTTGCTCTTGG 
(Shirwan et al., 1993) RTAC2 ATCCCGGGCAGAGGGTGATGTTATCAGACTGG 
RTAC3 GCTGGTACACAGCAGGCTCTGGG 
   
 TCR C-region primers  
RTCB.1   AAGGGCCCACCAGCTCAGCTCCACATGGTCAGG    
(Shirwan et al., 1993) RTCB.2 TACCCGGGCTCAAACAAGGAGACCTTGGGTGG     
RTCB.3 CATAGAATTCCACTTGGCAGCGGAAGTGGT 
   





 TCR  and  primers for amplification of full-length cDNA 
Rn_Va2 XbFw TCTAGAATGGACAAGATCCTGACAGCATC 
RnCaBH1.rev CCGGATCCACTGGACCACAGCCTTAGCGTCA 
Vbeta8.2 ApaFw GGGCCCATGTCAAACACTGCCCTCTCTAACTC 
RnVa13OVA#15.fw TCTAGAATGAAGGCATCCATTCACACTGTATTC 
Vb16-Ap1.fw GGGCCCATGGACAGCTGGCTGATTTTTAGTTGGA 





2.3 CELL CULTURE PROCEDURES 
2.3.1 CELL CULTURE MEDIA 
Table 2.5: Cell culture media compositions 
Medium  Composition Used for 
DMEM 
Gibco DMEM Powder (Invitrogen, Carlsbad, USA) 
1.2 g/l NaHCO3 (Carl Roth, Karlsruhe, Germany) 
Basic cell culture medium 
EH 
DMEM 
25 mM Gibco Hepes (Invitrogen, Carlsbad, USA) 
Cell suspensions from organs 
TCM = T cell medium 
DMEM 
1 % Gibco non-essential amino acids (Invitrogen, Carlsbad, USA) 
1 % Gibco sodium pyruvate (Invitrogen, Carlsbad, USA) 
1 % Gibco Penicillin/Streptomycin (Invitrogen, Carlsbad, USA) 
1:100 L-glutamine (Pan Biotech GmbH, Aidenbach, Germany) 
1:100 :-asparagine Monohydrate (Sigma Aldrich, Munich, Germany) 
4 l/l -mercaptoethanol (stock 13,6 M, Invitrogen, Carlsbad, USA)  
Basic medium for T cell and 
fibroblast culture 
TCM + 10% FCS TCM, 10 % Fetal Calf Serum (Biochom Ag, Berlin, Germany) Fibroblast culture 
RM (Restimulation Medium) TCM, 1 % rat serum T cell restimulation 
TCGF (T cell growth factor) 
TCM 
10 % horse serum (Biochom Ag, Berlin, Germany) 
5 % Conditioned medium from mouse splenocytes treated with the 
mitogen Concanavalin A (Sigma Aldrich, Munich, Germany) – 
(Rosenberg et al., 1978) 




80 % horse serum (Biochom Ag, Berlin, Germany) 
10 % DMSO (Carl Roth GmbH, Karlsruhe, Germany) 
Freezing of cells 
 
 
2.3.2 LENTIVIRUS PRODUCTION 
 
2.3.2.1 TRANSFECTION OF HEK 293T CELLS 
For preparation of lentiviruses, human embryonic kidney (HEK) 293T cells were transfected 
by the calcium phosphate method using a 3rd generation packaging system (Dull et al., 
1998) including two packaging plasmids (pRRE containing Gag and Pol and pRSV-Rev), 
one envelope plasmid (pMD2.g encoding for VSVG, Fig. 2.1) and the transfer plasmid 


































Figure 2.1: Schema of 3
rd
 generation packaging system vectors. 
 
HEK 293T cells were seeded at a density of 4 x 106 cells in a 10 cm dish (Sarstedt AG & 
Co, Nümbrecht, Germany) and cultured in TCM with 10 % FCS overnight (37°C, 5 % CO2).  
Prior to the transfection, 25 M choloroquine (Sigma Aldrich, Munich, Germany) was added 
to the medium for 30 min. Then, the transfer plasmids (20 g), pRRE (10 g), pRSV-Rev 
(5 g) and pMD2.g (6 g) were mixed in LoTE (10 mM Tris-HCl, 1 mM EDTA) to a volume 
of 440 µL. 60µl of 2.5 M CaCl2 and 500 l 2x HBS (50 mM HEPES, 280 mM NaCl, 1.5 mM 
Na2HPO4, pH 7.05) were added and incubated for 10 min. Transfection mixture was 
carefully applied to the cells. On the next day the medium was replaced with fresh TCM 
with 10 % FCS.  
 
2.3.2.2 LENTIVIRUS HARVESTING AND CONCENTRATION VIA 
ULTRACENTRIFUGATION 
Concentration of lentivirus was achieved by using ultracentrifugation. Therefore, the 
supernatant of the transfected 293T HEK cells was collected 48 h and 72 h post 
transfection and filtered through a 0.45 m pore size filter (Cole Parmer, Vernon Hills, IL, 
US) to remove cell debris. Then, the supernatant was transferred to 30 ml 
ultracentrifugation tubes (Beckmann Coulter, Fullerton, CA, US) and centrifuged (Sorvall 
Discovery 90SE, 70Ti rotor) at 26000 rpm for 2 h at 4°C. Afterwards, the supernatant was 
removed and the remaining pellet containing the lentivirus was resuspended in LoTE, 
aliquoted and stored at -80°C. 
 
2.3.2.3 DETERMINATION OF INFECTIOUS TITER IN HELA CELLS 
HeLa cells were seeded at a density of 10,000 cells per well in a 24-well plate (Nunc, 
Thermo Fischer Scientific Inc., Waltham, US) and transduced with different dilutions of the 
lentiviral preparation for 48 h at 37°C. Afterwards, the infectious titer was determined by 
flow cytometry analysis of HeLa cells for GFP expression. 
24 
 
2.3.3 PRIMARY T CELL CULTURE 
 
2.3.3.1 GENERATION OF RETROVIRAL PACKAGING CELL LINES 
Stable ecotropic retroviral packaging lines were generated using GP86+E mouse fibroblasts 
(Markowitz et al., 1988) as described (Flügel et al., 1999). Expression constructs are listed 
in Tab. 2.7. In brief, supernatant from transiently transfected Phoenix E cells was used to 
infect tunicamycin-pretreated GP86+E fibroblasts. Cells were then selected in puromycin- 
(2 g/ml) or neomycin-(1.5 mg/ml) containing medium, sorted by flow cytometry and 
subcloned by limiting dilution.  
 
Table 2.6: Fibroblast transducer cell line constructs for retroviral transduction of T cells 
Construct  Function Resistance Reference 
eGFP Enhancement of fluorescent signal for microscopy Neomycin (Flügel et al., 1999) 
 
2.3.3.2 PRIMARY T CELL CULTURE 
Naïve Lewis rats were immunized with myelin basic protein in Complete Freund’s Adjuvant 
(see chapter 2.4.2). 
For retroviral transduction of T cells, packaging cells (GP86+E mouse fibroblasts) were 
seeded into round-bottom 96-well plates (Nunc, Thermo Fischer Scientific Inc., Waltham, 
US) at a concentration of 15,000 cells/well in restimulation medium at the day of lymph 
node harvest.  
On day 10 post immunization, draining lymph nodes were harvested in cold EH buffer. A 
single-cell suspension of the tissue was prepared under the laminar flow hood and added to 
the GPE-containing 96-well plates at a concentration of 200,000 cells/well and with the 
addition of antigen at a concentration of 10 g/ml. On day 2, TCGF medium containing 
growth factors was added to the cells and if necessary supplemented with antibiotics for cell 
selection.  
On day 7, T cells were restimulated by the addition of 1.4 x 106 30 Gy-irradiated syngeneic 
thymocytes per well in restimulation medium with 10 g/ml antigen. 2 days later, TCGF was 
added to the cells thereby supplementing antibiotics for cell selection. 24 hours later the 
best wells were chosen based on the cell’s fluorescence and growth appearance and 
pooled into 60 mm dishes. 
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For further restimulations, 3.5 x 106 T cells were mixed with 70 x 106 irradiated syngeneic 
thymocytes and 10 g/ml antigen per 60 mm dish and supplied with TCGF medium on day 
2 after restimulation. 
 
2.3.3.3 CELL COUNTING 
The number of living cells within a cell suspension was determined using a hemocytometer. 
The cell suspension was diluted with 0.04 % trypan blue (Sigma Aldrich, Munich, 
Germany). 10 l of the dilution were applied to a hemocytometer and living cells counted 






/10** 4   
 
2.3.3.4 CRYOCONSERVATION OF CELLS 
Cells were pelleted and resuspended in ice cold freezing medium. 1.5 ml of cell suspension 
were transferred into cryo tubes (Nunc, Thermo Fischer Scientific Inc., Waltham, US) and 
immediately stored at -80°C in a freezing chamber (Nunc, Thermo Fischer Scientific Inc., 
Waltham, US). For longer storage, cells were placed at -192°C in liquid nitrogen. 
Cells were thawed by placing the cryo tube in a 37°C water bath and transferred into a 
50 ml Falcon (Greiner Bio-One International AG, Kremsmünster, Austría) containing 10 ml 






2.4 ANIMAL EXPERIMENTS 
 
2.4.1 CARETAKING AND MAINTENANCE 
Lewis rats aged 6-8 weeks were obtained from the animal facility of the University Medical 
Center Göttingen (UMG). Animal experiments were performed in accordance with local 
regulations for animal wellfare of Lower Saxony.  
Table 2.7: Lewis rat strains used in this study 
Rat strains Genetic Background 
Lewis rat Wild type 
rMT-II 
Transgenic MBP-specific T cell receptor expression coupled to GFP expression 
Lewis rat background 
rOT-II 
Transgenic OVA-specific T cell receptor expression coupled to GFP expression 
Lewis rat background 
AsRed Transgenic Lewis rat strain expressing RFP under the control of a ubiquitin C promoter (Lodygin et al., 2013) 
 
2.4.2 IMMUNIZATION 
For analysis of active EAE and for establishing T cell cultures, naïve wild type Lewis rats, 
rMT-II or rOT-II TCR transgenic Lewis rats were immunized with antigen (guinea pig myelin 
basic protein or chicken ovalbumin) in Complete Freund’s Adjuvant (CFA, Tab 2.8). Antigen 
emulsion was prepared by mixing equal volumes of the respective antigen (1 mg/ml stock 
solution in PBS) and CFA (4 mg/ml stock solution in mineral oil) using two tuberculin glass 
syringes (POULTEN & GRAF GmbH, Wertheim, Germany) joint via a custom made 
connector. 150 l of this emulsion were injected subcutaneously close to the tail base (50 l 
on each side) and the inner side of the hind limbs (25 l on each side) of rats anesthetized 
by dimethyl ether. 
 
Table 2.8: Reagents for immunization 
Antigen Source 
Guinea-pig myelin basic protein Prepared from guinea pig brains as described (Eylar, 1978) 
Chicken ovalbumin Sigma Aldrich, Munich, Germany 
Adjuvant  
Complete Freunds Adjuvant 
Incomplete Freunds Adjuvant  (Difco, Becton Dickinson, Franklin Lakes, NJ, USA) 




2.4.3 ADOPTIVE TRANSFER EAE 
For triggering transfer EAE, fully activated T cell blasts (3-5 x 106 per rat) were injected into 
the tail vein of naïve Lewis rats anaesthetized with dimethyl ether. The rats were weighted 
and scored daily (or twice a day around the onset phase) for clinical symptoms (Tab 2.9). 
The same scoring system was used for active EAE experiments. Animals reaching a score 
of 3.5 were eliminated. 
Table 2.9: Scoring system for rat experimental autoimmune encephalomyelitis 
Score Clinical Symptom 
0 No symptoms 
0.5 Partial loss of tail tonus 
1 Flaccid tail (complete loss of tail tonus) 
1.5 Flaccid tail and subtle gait disturbance 
2 Pronounced weakness of hind limbs, progressed gait disturbance 
2.5 Pronounced weakness of hind limbs, impaired adduction of hind limbs, paralysis of a single hind limb 
3 Paraplegia (complete hind limb paresis); animals are able to actively move forward using their fore limbs  
3.5 Weakness of fore limbs leading to impaired forward movement 
4 Tetraplegia  
5 Moribund or dead 
 
2.4.4 SUBCUTANEOUS TRANSFER OF T CELLS 
Naïve T cells were obtained from spleens of naïve transgenic rMT-II or rOT-II rats. Spleens 
were harvested and plated in 10 cm polystyrene Petri dishes containing 15 ml EH medium 
supplemented with 2 mM EDTA for 30 min at 37°C. During the incubation, macrophages 
and dendritic cells adhere to the plate. Afterwards the floating non-adherent cells (mainly T 
cells and B cells) were collected, washed once and resuspended in EH medium with 
5 x 106 cells/20 l. For subcutaneous transfer, rats were anaesthetized with dimethyl ether 
and 20 l of the cell solution were injected into the inner side of the right hind limb. 
Approximately 16 h post transfer, the recipients were immunized with antigen in CFA 
(20 l/rat) at the same location. 
Resting effector T cells (meaning  T cell lines 6 days after the last antigen stimulation) were 
taken up in EH medium at a concentration of 5 x 106 T cells/20 l  and transferred into 
animals as described above. 
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2.4.5 INTRATHECAL INJECTIONS 
Rats were anesthetized by a subcutaneous injection of xylazine (10 mg/kg) and ketamine 
(50 mg/kg). With a stereotactic device the head of the rat was fixed by ear bars, tilted 
downward to almost 90° and secured by the tooth holder. The site of injection between the 
cervical vertebrae C1 and C2 was disinfected with 70 % ethanol. For injection a 0.5 ml 
tuberculin syringe (Becton Dickinson, Franklin River, NJ, USA) fixed to the manipulator arm 
was used. The needle was slowly inserted until it reached the cerebrospinal fluid which was 
ascertained by aspiration of liquor. Then a total volume of 30 l was injected over a time 
period of 10 min. 
 
2.4.6 EUTHANASIA 
For euthanasia, rats were placed in a chamber slowly flooded with CO2.  
 
2.4.7 PERFUSION 
Rats were perfused with paraformaldehyde (PFA, CARL ROTH GmbH, Karlsruhe, 
Germany) to preserve the tissue for histological analysis. After euthanizing the rat with CO2, 
the thorax was opened up and the heart was exposed. The pericard was removed and an 
incision made into the left ventricle. Then, a cannula connected to a pump via flexible tubes 
(ISM596B, Ismatec, Wertheim, Germany) was inserted into the left ventricle and fixed with 
a clamp. Additionally, an incision was made into the right atrium and the pump was started 
with a flow-rate of 10.71 m/s of 1 x PBS to flush out the blood. After 20 min the solution was 
switched to 4 % PFA for another 20 min. After the perfusion, organs were harvested and 
stored in 4 % PFA for further processing. 
 
2.4.8 LENTIVIRUS MICROINJECTION INTO RAT OOCYTES 
Generation of transgenic Lewis rats was performed as reported (Mullins and Mullins, 1996) 
by Dr. Jens van den Brandt and Dr. Henrike Fischer, Institute of Cellular and Molecular 
Immunology, working group of Experimental Immunology (Prof. Dr. Holger Reichardt), 
University Medical Center, Göttingen.  
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Briefly, a solution containing concentrated lentivirus was injected into the perivetelline 
space of single cell embryos isolated from superovulated Lewis females mated on the 
previous night with Lewis males. Injected zygotes were cultured overnight and as two-cell 
stage embryos transferred into the oviduct of pseudopregnant recipient Wistar females.  
 
2.4.9 GENERATION OF BONE MARROW CHIMERAS 
For the generation of bone marrow chimeras, naïve female Lewis rats (age 8-10 weeks) 
were irradiated with 10 Gy using a X-ray counter kindly provided by the Department of 
Radiotherapy, UMG Göttingen. Therefore, naïve recipients were anaesthesized with 
ketamine/xylazin (50 mg/kg / 10 mg/kg), placed in the irradiation chamber in groups of 5 
rats and irradiated with 1 Gy per minute.  
The next day, rOT-II or AsRed donor rats were killed in CO2 and the femur and tibia were 
collected in cold EH medium. The bone marrow was flushed out with EH medium using a 
5 ml syringe (BBraun Melsungen AG, Sempach, Switzerland) with a 30 G needle (BD 
Microlance 3, Becton Dickinson, Franklin Lakes, NJ, USA). Cells were collected and 
incubated in AcK buffer to destroy erythrocytes. Afterwards, bone marrow cells were 
resuspended in EH, counted and adjusted to a concentration of 20 x 106 cells per ml. For 
bone marrow reconstitution, irradiated recipient rats were anaesthetized and the bone 
marrow cell suspension injected intravenously using a 1 ml syringe with a 22 G needle 
(BBraun Melsungen AG, Sempach, Switzerland). Reconstituted recipients were observed 
and weighed daily for a period of two weeks and blood samples were then analyzed for 





2.5 IMMUNOLOGICAL METHODS 
2.5.1 PREPARATION OF CELL SUSPENSIONS FROM ORGANS 
Organs were collected in EH for further processing. Lymph nodes and spleen were brought 
to suspension by smashing the organs through a metal mesh (provided by UMG Göttingen, 
in-house machine shop) using a pistil (BBraun Melsungen AG, Sempach, Switzerland). The 
homogenized organs were taken up, washed once and resuspended in EH medium. 
 
2.5.2 ERYTHROLYSIS  
Erythrocytes residing e.g. in spleen disturb FACS analysis of cell suspensions. To deplete 
erythrocytes, cell pellets were resuspended in 5 ml ACK buffer and incubated for 5 min on 
ice. Afterwards, cells were washed in PBS and resuspended in EH medium. 
 
2.5.3 CELL ISOLATION FROM BLOOD 
Isolation of lymphocytes from blood was achieved using a density gradient based on Ficoll 
and sodium diatrizoate (Lymphocyte Separation Medium, Lonza, Walkersville, US). The 
blood was placed on top of the LSM solution and centrifuged for 30 min at 1600 rpm with 
slow deceleration. Lymphocytes, that made up a ring within the transparent fraction of the 
gradient, were collected and stored in EH medium. 
 
2.5.4 CELL ISOLATION FROM SPINAL CORD USING A PERCOLL GRADIENT 
Isolation of mononuclear cells from spinal cord tissue or meninges was achieved using a 
Percoll gradient. To this extend, the tissue was smashed through a metal mesh and taken 
up in EH. A cell suspension of 35 ml EH was prepared and mixed with 15 ml of isotonic 
Percoll (1,124 mg/ml) prior to centrifugation (20°C, 30 min, 3780 rpm without acceleration 





2.5.5 SEPARATION OF T CELLS VIA MAGNETIC SORTING 
T cells were isolated from pooled spleen and lymph node preparations via negative 
selection.  
To this extend, cells were incubated with biotinylated antibodies or antibodies labeled with 
tetrameric avidin complexes (StemCell Technologies, Newark, NJ, USA) directed against 
cell surface markers for macrophages, B cells and NK cells (OX-42, OX-33 and anti-
CD161) in 1 ml PBS with 2 % FCS and 2 mM EDTA per 5 x 107 cells for 5 min at RT. Then, 
a TAC-conjugated anti-biotin antibody was applied for additional 5 min at RT. As a last 
incubation step, anti-TAC magnetic beads were added for 5 min at RT. The volume was 
increased to 8 ml with buffer and the tube placed in an EasySep medium magnet for 
separation of labeled and non-labeled cells. After 7.5 min, the magnet together with the 
tube was inverted and the buffer containing the T cell fraction was collected in a fresh tube.  
Further division of naïve and memory T cells was achieved with the same method using a 
TAC-conjugated antibody directed against CD62L. 
 
2.5.6 PROLIFERATION ASSAY 
T cells (5 x 104 cells/well) were co-cultured with 30 Gy-irradiated syngeneic thymocytes 
(1.2 x 106 cells/ml) in 100 l RM per well and stimulated either with CD3 and CD28 
antibodies or with the indicated concentrations of different antigens. MHCII-restriction was 
tested via blocking of the CD4-MHCII interaction using the -rat OX-6 antibody.  
Lymph node suspensions were incubated with antigen in RM using 0.3 x 106 cells/well. 24 
hours after stimulation, radioactive thymidine [3H]dT (GE Healthcare Life Sciences, 
Uppsala, Sweden, 2 Ci/mmol) was added to the culture and radioactive counts were 
measured 16 hours later using a β counter (MicroBeta Trilux 1450LSC, PerkinElmer, 
Waltham, MA, US). 
 
Table 2.10: Antibodies used for cell culture assays 
 Host Clone Concentration Company 
α rat RT1B mouse OX-6 1 g/ml BD Biosciences, San Jose, CA, USA 
α rat CD3 mouse G4.18 1 g/ml BD Biosciences, San Jose, CA, USA 




2.5.7 ENZYME-LINKED IMMUNOSORBENT ASSAY 
Measurement of cytokine production of T cells in the supernatant was performed using 
commercially available double-sandwich ELISA kits according to the manufacturer’s 
instruction (rat-IFN and rat-TNF, BD Biosciences, San Jose, CA, USA). 
Briefly, 96-well plates with a polystyrene based surface (Nunc, Thermo Fischer Scientific 
Inc., Waltham, US) were coated with a cytokine specific Capture Antibody in a 0.2 M 
sodium azide buffer at 4°C overnight. The next day, the plate was washed with ELISA 
washing buffer (1x PBS + 0.05 % Tween-20 (CARL ROTH GmbH, Karlsruhe, Germany)) 
and blocked with PBS with 10 % FCS for 1 hour at room temperature prior to the next 
washing procedure. For qualitative measurement of the sample’s cytokine content, a 
standard curve was added by preparing a serial 1:2 dilution of a maximum standard with 
recombinant cytokine. After adding the standard dilutions and the samples, the plate was 
incubated for 2 h at RT and washed afterwards. A second cytokine specific biotinylated 
Detection Antibody was added to the plate and incubated for 1 h at RT prior to a next round 
of washing. Next, the plate was incubated for 30 min with the enzyme horseradish 
peroxidase (HRP) coupled to streptavidin for 30 min and then washed extensively. 
Afterwards, the substrate tetramethylbenzidine (TMB) together with H2O2 was added and 
incubated for 30 min in the dark. HRP catalyzes the oxidation of TMB to benzidine blue. 
The reaction was stopped via addition of acid sulfur and the plate measured with an ELISA 
reader at 450 nm wave length. For analysis, the optical density of the sample wells was 
correlated with the optical density measured for the standard dilutions and the 
concentration of the cytokines calculated. 
 
2.5.8 FACS ANALYSIS OF CELL SURFACE MARKER 
USING FLUORESCENTLY LABELED ANTIBODIES 
For cell surface staining with fluorescently labeled antibodies, 1 x 106 cells were 
resuspended in 100 l FACS buffer containing the respective antibodies (see Tab. 2.11) 
and incubated on ice for 20 min. Cells were centrifuged for 2 min at 1200 rpm and either 
incubated with a secondary antibody in 100 l FACS buffer for another 20 min or directly 
resuspended in 200 l FACS buffer and transferred into 5 ml FACS tubes (BD Biosciences, 
San Jose, CA, US) for analysis. 
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2.5.9 INTRACELLULAR STAINING OF CYTOKINES  
Intracellular cytokines were trapped in the Golgi apparatus of restimulated cells by 
treatment with Brefeldin A (1 g/ml, Sigma Aldrich, Munich, Germany) 48 h after 
restimulation. After 3 h at 37°C with 5 % CO2, cells were centrifuged and fixed in 2 % PFA 
for 20 min on ice prior to a pretreatment with 1 x BD Perm/Wash buffer (30 min on ice, BD 
Biosciences, San Jose, CA, US). Afterwards, cells were resuspended in 1 x BD Perm/Wash 
Buffer containing IFN-AlexaFluor647 and  IL-17-PE antibodies, incubated for 1 h on ice 
and then resuspended in 200 l FACS buffer and transferred to 5 ml FACS tubes. 
 
2.5.10 FACS ANALYSIS AND SORTING OF FLUORESCENTLY LABELED CELLS 
FACS analysis of cell surface molecules was performed using the flow cytometer FACS 
Calibur instrument (BD Biosciences, San Jose, CA, USA). Briefly, this system consists of 
two lasers, an air-cooled argon laser (488 nm excitation) and a red diode laser (640 nm 
excitation) enabling the possibility of measuring four fluorescent parameters. 
For cell sorting, the flow cytometer BD FACS AriaIII (BD Biosciences, San Jose, CA, USA) 
was used equipped with a four-laser system (488 nm, 561 nm, 633 nm and UV). Cells were 
taken up in EH medium containing 2 mM EDTA and sorted for expression of GFP or 
surface molecules (e.g. CD62L) at minimum flow-rate of 1000-2000 events/second at 4°C 
reaching a purity of 90-95 %. The collection tube contained EH medium supplemented with 
10 % FCS. Collected cells were centrifuged and taken up in RLT buffer (Qiagen, Hilden, 




Table 2.11: FACS antibodies 
Primary Target Host Clone Label Dilution Company* 
α rat TCR mouse R73 AlexaFluor 647 1:400 Biolegend 
α rat TCR mouse V65 PE 1:400 Biolegend 
α rat CD25 mouse OX-39 PE 1:400 Biolegend 
α rat CD45RA mouse OX-33 PE 1:250 Biolegend 
α rat CD45RC mouse OX-22 PE 1:300 Biolegend 
α rat CD44H mouse OX-49 AlexaFluor 647 1:200 Biolegend 
α rat CD8 mouse OX-8 PE 1:400 Biolegend 
α rat CD8 mouse OX-8 biotinylated 1:200 BD Pharmingen 
α rat CD8 mouse 341 AlexaFluor 647 1:400 Biolegend 
α rat CD4 mouse OX-35 PECy5 1:400 BD Pharmingen 
α rat V16 mouse HIS42  1:100 AbD Serotec 
α rat V8.2 mouse R78  1:100 SantaCruz Biotechnologies 
α rat V8.5 mouse G101  1:100 AbD Serotec 
α rat TCR mouse R73 biotinylated 1:200  
α rat CD3 mouse 1F4 AlexaFluor 647 1:400 Biolegend 
α rat CD134 mouse OX-40 biotinylated 1:100  
α rat RT1B mouse OX-6 FITC 1:100 AbD Serotec 
α rat CD62L mouse OX-85 PE 1:250 Biolegend 
α rat CD11b/c mouse OX-42 AlexaFluor 647 1:200 AbD Serotec 
α rat IFN mouse DB-1 AlexaFluor 647 1:100 Biolegend 
α rat IL-17A mouse TC11-18H10 PE 1:100 BD Pharmingen 
α rat CD161 mouse 10/78 AlexaFluor 647 1:200 Biolegend 
      
Isotype Controls      
IgG1 mouse MOPC-21 AlexaFluor 647 1:100 Biolegend 
IgG1 k mouse R3-34 PE 1:100 BD Pharmingen 
      




 APC 1:200 Jackson ImmunoResearch 
Streptavidin-APC   APC 1:500 Biolegend 
Streptavidin-PE   PE 1:500 Biolegend 
Streptavidin-FITC   FITC 1:500 Biolegend 
Streptavidin-PECy5   PE-Cy5 1:500 Biolegend 
  
*Biolegend (London, UK), BD Pharmingen (San Diego, CA, US), AbD Serotec (Kidlington, UK), SantaCruz 






2.6.1 PREPARATION AND SECTIONING 
Tissues fixed in PFA were embedded in Tissue-Tek (Sakura Finetek, Alphen, The 
Netherlands) and sectioned using a cryostat (Leica CM-3050-S,Wetzlar, Germany). Slices 
of the tissue with a thickness of 12 m were mounted on microscope slides (Thermo 
Fischer Scientific Inc., Waltham, US) and stored at -20°C.    
2.6.2 IMMUNOHISTOCHEMISTRY 
Tissue slides were stained for different markers using fluorescent antibodies.  
To this extend, slides were thawed and once again fixed in 4 % PFA for 5 min. Spinal cord 
sections afterwards were incubated in ice cold methanol with H2O2 for 5 min and then 
washed 3 x 5 min in 1 x PBS. To avoid unspecific binding of the antibody, the slides were 
blocked with 10 % FCS and 0.05 % Trition-X-100 (Carl Roth GmbH, Karlsruhe, Germany) 
in 1 x PBS for 30 min at room temperature. The primary antibody was diluted in 1 % FCS 
with 0.05 % Triton-X-100 and applied to the slides overnight at 4°C. The next day, the 
slides were washed (3 x 5 min in 1 x PBS) and if necessary incubated with the secondary 
antibody for 30 min at room temperature. The slides were washed as before and subjected 
to a DAPI staining for 5 min. After a last round of washing, the slides were covered with 
Fluoromount (Southern Biotech, Birmingham, AL, US) to preserve the fluorescent signal 
and a cover slip (Thermo Fischer Scientific Inc., Waltham, US). 
 
Table 2.12: Antibodies used for immunohistochemistry 
Primary Host Clone Dilution Company 
 rat TCR mouse R73 1:500 Biolegend, London, UK 
 rat CD68 mouse ED-1 1:250 AbD Serotec, Kidlington, UK 
 rat Iba1 rabbit polyclonal 1:250 Wako Chemicals GmbH, Neuss, Germany 
 rat GFAP rabbit polyclonal 1:250 Dako, Hamburg, Germany 
 rat CNPase mouse SMI 91 1:200 Sternberger Monoclonals Inc., Baltimore, MD, US 
 mouse-Cy3 goat  1:1000 Jackson ImmunoResearch, West Grove, PA, US 
 rabbit-AF633 goat  1:1000 Invitrogen, Carlsbad, CA, US 






Epifluorescent microscopy was performed using a Zeiss Axio Observer Fluorescence 
Microscope in combination with an HXP120C illuminator routed through a Zeiss Plan 
Apochromat 310 Air Objective. Fluorescent signals were detected using a Zeiss AxioCam 
HSM video camera. 
Confocal microscopy was performed using a LSM 710 equipped with a Plan-Apochromat oil 
40x/1.3 (UV) VIS-IR objective and operated by ZEN2009 software (Carl Zeiss, Jena, 
Germany). 
 2.7 TWO-PHOTON LIVE CELL TRACKING IN THE CNS 
2.7.1 TWO-PHOTON LIVE CELL TRACKING IN THE CNS: PROCEDURE 
Two-photon live imaging experiments were performed by Dr. Christian Schläger as 
described before (Bartholomaus et al., 2009). 
Briefly, animals were anaesthetized with ketamine (50 mg/kg) and xylazine (10 mg/kg), 
intubated and further ventilated with 1.5-2 % isoflurane (Baxter GmbH, Höchstadt a.d. 
Aisch, Germany). Vital parameters were recorded using Animal Monitor software 7.3x 
(Volker Staiger, Max-Planck Institute of Neurobiology, Martinsried, Germany) and body 
temperature was controlled (37 – 37.5°C) using a heated pad (Telemeter Electronic GmbH, 
Donauwörth, Germany).  
Live imaging of T cells in the leptomeninges was achieved by preparing a spinal cord 
window at the level of Th12/L1 by laminectomy. During imaging, spinal cord tissue was 
prevented from dehydration by covering the tissue with a sodium chloride solution (B.Braun 
Melsungen AG, Melsungen, Germany). 
Technically, two-photon live imaging of T cells was performed using a LSM710/Axio 
Examiner. Z1 confocal microscope (Carl-Zeiss Microimaging, Jena, Germany) combined 
with a >2.5Watts Ti:Sapphire Chameleon Vision II Laser device (Coherent GmbH, Dieburg, 
Germany). Exitation wave lengths were tuned to 880 nm or 1010 nm. One recording usually 
covered a 424.27 x 424.27 m (512 x 512 px) or 2121.35 x 424.27 m (2560 x 512 px) area 
with a tissue depth of 50-100 m. The interval time of the recordings were set to 32 sec or 
120 sec, respectively. Recordings were acquired and initially processed using the Zen 2009 
Software (Carl-Zeiss Microimaging, Jena, Germany) and afterwards edited using ImageJ 
1.46i software (National Institute of Health, Bethesda, USA). 
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2.7.2 TWO-PHOTON LIVE CELL TRACKING IN THE CNS: ANALYSIS 
Parameters of T cell motility (velocity, crawling duration and meandering index) were 
obtained by analyzing the recordings with the Imaris 7.1.1 software (Bitplane, Zurich, 
Switzerland) with an automated Imaris Track module. 
  
2.8 STATISTICS 
Statistical analysis was performed using the Prism software (GraphPad Software Inc., San 
Diego, CA, US). Data is always depicted as mean ± standard error of the mean (SEM). For 
all analyses student’s unpaired t-test was used (p-value > 0.05: ns, p-value ≤ 0.05: *, p-







3.1 GENERATION AND CHARACTERIZATION OF TCR TRANSGENIC RATS 
3.1.1 MBP-SPECIFIC TCR TRANSGENIC RATS 
3.1.1.1 CLONING OF A MBP-SPECIFIC TCR  
To obtain the DNA sequence for the reconstruction of the myelin basic protein specific 
T cell receptor we used mRNA isolated from the “self-cloned” Lewis rat T cell line Z85. In 
this line the variable segment of the ß chain is known to be Vß8.2 for which a monoclonal 
antibody is available.  
Initially, we performed rapid amplification of cDNA 5’-ends (5’-RACE) PCR using gene 
specific primers binding the constant region of the TCR ß-chain. Sequencing of the 
amplified PCR product revealed the previously described composition of the ß chain-  
V8.2-J1.3-C1 (Chluba et al., 1989) with the leader exon distinct from the one described 
earlier, but matching the rat Vß8.2 5’-end sequence published elsewhere (Smith et al., 
1991). For identification of the -chain, a PCR was performed using a set of primers 
recognizing families of V-chains (Buenafe et al., 1997) and a reverse primer binding within 
the constant region of the -chain (Fig. 3.1 A). The resulting PCR products (V1 and V2) 
were sequenced and only the sequence of the V2-PCR fragment (V2.5-J26-C) 
seemed to contain an intact open reading frame (Fig. 3.1 B). The sequence was blasted 
against the rat genome NCBI database and the next upstream coding leader exon was 
identified by comparison to known sequences of the mouse V2 family of genes (Arden et 
al., 1995).   
The PCR products for both full length -chain and the -chain were cloned into shuttle 
vectors and then fused together via a modified version of the 2A-like linker (P2A, Szymczak 
and Vignali, 2005) to generate a bicistronic expression cassette. The fused V2.5-P2A-
V8.2 chain was cloned into pEGFP-T2A-C1er, a modified version of the pEGFP-C1 vector 
(Clontech) with a built-in T2A linker and an additional EcoRI restriction site (pEGFP-T2A-
V2.5-cP2A-V8.2). Then, the tricistronic expression cassette was transferred into the 
lentiviral expression vector pFUGW previously used for generation of transgenic mice (Lois 
et al., 2002; Fig. 3.1 C).  
To assess the surface expression and the functionality of the cloned TCR, TCR-/- thymoma 
BW58C cells expressing a chimeric rat-mouse CD28 were cocultured with lentiviral 
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concentrate for 48 h and analyzed for V8.2 surface expression (34 % of GFP+ V8.2+ 
hybridoma cells, Fig. 3.1 D). The transduced BW58C-TCR cells were then mixed with rat 
thymic antigen presenting cells and challenged with different concentrations of MBP 
resulting in a dose-dependent production of interleukin-2 (IL-2) in response to the specific 
antigen MBP but not to OVA (Fig 3.1 E). Taken together, these results proved the correct 
structure of the cloned TCR as it could be expressed on the cell surface and its specificity 
and functionality as transduced cells responded to the cognate antigen. 
 
3.1.1.2 ANALYSIS OF rMT-II FOUNDER ANIMALS  
Generation of TCR transgenic Lewis rats was achieved by injecting a concentrated lentiviral 
preparation into the perivitelline space of fertilized oocytes. Zygotes further developing into 
the two-cell embryo stage during overnight culturing were transferred into pseudopregnant 
Wistar rat foster females. The rat pups were genotyped and phenotyped three weeks after 
birth.  
For genotyping, genomic tail DNA was used as PCR template with primers binding within 
the P2A sequence and the variable segment of the V8.2 chain. In the peripheral blood of 
these animals a low amount of GFP-positive T cells was detected by FACS analysis but no 
increased V8.2 expression (Fig. 3.1 G). 
Founder animals positive for integration (Fig. 3.1 F) were mated among each other and the 
F1 generation was again phenotyped by analyzing blood lymphocytes three weeks after 
birth. In the F1 generation, almost all CD4+ T cells expressed GFP and showed increased 
numbers of V8.2+ cells. We have named the new strain rMT-II, standing for rat MBP-
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Figure 3.1: Reconstruction of the Lewis rat MBP-specific T cell receptor. (A) V-chain PCR on cDNA template derived from the 
MBP-specific T cell line Z85 showed a positive signal for V1 and V2 gene families. (B) Cloned amino acid sequence for the 
CDR3 region of  and ß TCR chains. C, constant region; J, junction segment; D, diversity segment; V, variable segment; n, 
nontemplated nucleotides. (C) Schematic of the lentiviral expression construct. Open reading frames for GFP, TCR and TCR 
were fused via T2A and P2A sequences and are expressed under the control of the ubiquitin C promoter. Restriction sites used 
for replacing EGFP by a tricistronic cassette are indicated. (D) Coexpression of GFP and V8.2 TCR in the lentivirally 
transduced TCR-negative BW58C T cell hybridoma cell line. (E) Induction of mouse IL-2 in response to stimulation with MBP. 
Concentration of mouse IL-2 was measured by ELISA in supernatants from lentivirus-transduced hybridoma cocultured with 
Lewis rat APC in the presence of the indicated amount of MBP or OVA. Graphs are depicted as Mean ± SEM. (F) Founder 
animals which integrated the transgenic construct were identified by genomic PCR using primers specific for the expression 
cassette. (G) FACS analysis of blood cells from founder animal no. 4 (F), stained with mAb specific for TCR-Vß3.3 and TCR-
Vß8.2 (transgenic chain).  Data shown in (G) was generated by Dr. Henrike Fischer, Department of Immunology, laboratory of 
Prof. Holger Reichardt.    
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3.1.1.3 rMT-II RATS EXPRESS GFP AND THE TRANSGENIC T CELL RECEPTOR  
Crossing of F1 rMT-II animals yielded progenies with no, moderate or high GFP expression 
in frequencies fitting to Mendelian inheritance (Fig 3.2 A, data not shown). Breeding of rats 
with high GFP expression resulted in animals which were uniformly “high-GFP” suggesting 
that those rats are homozygous for the rMT-II allele (rMT-II+/+). In rMT-II+/+ rats, the GFP 
expression levels varied between cell types: it was highest in myeloid cells and NK cells, 
intermediate in T cells, and lowest in B cells (Fig. 3.2 B). 
Both rMT-II+/- and rMT-II+/+ rats showed a significant increase in T cell numbers expressing 
the transgenic V8.2 chain (Fig. 3.2 C). In these animals, the V8.2+ T cells could be further 
divided into a TCRmedium-V8.2high (red square) and a TCRhigh-V8.2medium (purple square) 
population with the TCRmedium-V8.2high population being dominant in rMT-II+/+ rats. 
Additionally, rMT-II+/- rats still possessed a V8.2+-population expressing TCR at levels 
similar to WT littermates. These presumably contain a productively rearranged endogenous 
TCRß gene. Also, T cells in rMT-II+/- rats expressed other endogenous Vchains (V8.5 














































































nontransgenic (WT) Lewis rats. (B) GFP expression levels in immune cells of rMT-II
+/+
 Lewis rats. (C) Expression of V-chains in 













 (purple square). (D) Quantification of V8.2
+
 T cells in blood 




 rats. (C) and (D) gated on GFP
+
 lymphocytes. Data obtained by immunostaining 




3.1.1.4 COMPOSITION OF THE IMMUNE SYSTEM OF rMT-II RATS  
Further, we analyzed the cellularity of lymphoid organs. Whereas the cell numbers were 
similar between the genotypes in thymus, spleen and blood, a significant reduction of the 
total cell number was observed in lymph nodes (pooled inguinal, popliteal, axillary, cervical, 
paraaortic and mesenterial lymph nodes) of rMT-II+/+ rats. In WT Lewis rats, around 
360 x 106 cells were counted per gram organ but were diminished to 250 x 106 cells per 
gram organ in rMT-II+/- rats and further decreased to 180 x 106 cells per gram organ in rMT-
II+/+ rats (Fig 3.3 A).  
To address whether the reduced cell number is due to a reduction of T cell numbers, lymph 
node and blood cells were stained for the expression of T cell receptor and CD45RA, a 
marker for B cells. As shown in Figure 3.3 B and C, rMT-II+/- rats showed a decreased 
percentage of T cells and decreased ratio of T cell number/B cell number (T/B). In rMT-II+/+ 
animals, the relative number of T cells and the T/B ratio in lymph nodes returned to WT 
levels, whereas in blood the T/B ratio was lower than in blood of WT littermates.    
It was reported before, that distortion of thymic development occurs in TCR transgenic mice 
(e.g. Barnden et al., 1998; Lacorazza et al., 2001). Therefore, we analyzed thymi and 
peripheral lymphoid organs from WT and transgenic rats for the expression of CD4 and 
CD8 surface markers. In WT Lewis rats, around 85 % of thymocytes are double-positive 
(DP) for CD4+ and CD8+ whereas around 6 % are CD4+ and 5 % are CD8+ single-positive 
(SP) thymocytes (van den Brandt et al., 2005). Unexpectedly, in the thymus of rMT-II+/- rats 
we observed a strong reduction in the CD4+ SP population to 0.7 %, while proportions of 
CD8+ SP and DP cells were slightly increased (Fig. 3.3 D, 7 % and 88 %, respectively). 
There was no accumulation of cells within the double-negative (DN) population. 
Nevertheless, in the periphery of rMT-II+/- rats, the majority of T cells were CD4+ (60%, 
Fig. 3.3 E). In homozygous rMT-II+/+ animals, the percentage of CD4+ SP thymocytes was 
restored to 3.9 %, whereas the relative size of the CD8+ SP population was significantly 
increased (9.4 %, Fig. 3.3 D). Interestingly, in rMT-II+/+ lymph nodes (and blood) the single-
positive CD8+ population was reduced to only 5-6 % (versus 25 % in WT) and the vast 










































































































































































Figure 3.3: (A) Total cellularity of different lymphoid organs was determined by cell counting. Shown are numbers per g of 
organ or ml of blood in millions of cells. Percentages of GFP
+
 T cells and B cells in lymph nodes (B) and blood (C) determined 
by flow cytometry. (D,E) Representative FACS plots of CD4/CD8 stained cells isolated from thymus (D) and lymph nodes (E). 
Quantification of CD4/CD8 expressing GFP
+
 lymphocytes depicted on the right. n=3 per genotype. Graphs depicted as Mean ± 




NK cells belong to the innate immune system whereas NK T cells are a subpopulation of T 
cells recognizing lipid antigens in the context of the coreceptor CD1d. We analyzed the 
expression of CD161 (also known as NK1.1) and TCR in lymph nodes, spleen and in the 
blood of transgenic rats and found that both NK and NK T cell numbers were slightly 
increased in rMT-II+/+ animals (Fig. 3.4 A, data shown for lymph nodes only).  
Besides developing into T cells, progenitor cells entering the thymus can develop into 
T cells, a distinct T cell lineage expressing a TCR consisting of a  and a  chain.  
As shown in Figure 3.4 B, in WT 1.4 % of all CD3+ cells in the lymph nodes (blood 1.2 %) 
were T cells. The amount of lymph node T cells was significantly reduced to 0.76 % in 














































Figure 3.4: (A) Percentages of NK and NK T cells in lymph nodes gated on GFP
+
 cells. (B) Percentages of T cells in the lymph 




 cells. n=3 per genotype. Graphs depicted as Mean ± SEM. 
 
3.1.1.5 EX VIVO ANTIGEN RESPONSE OF rMT-II T CELLS  
To address antigen specificity of rMT-II T cells, total lymph node cell preparations were 
stimulated in vitro with different concentrations of MBP protein isolated from guinea pig 
brains or synthetic MBP68-88 peptide (immunodominant epitope of MBP in Lewis rats; this 
peptide is also recognized by the Z85 cell line). As a positive control, cells were stimulated 
with plate-bound monoclonal antibodies to rat CD3 and rat CD28 robustly inducing 
proliferation and production of cytokines. 48 h after stimulation, cultures were pulsed with 
[3H]-thymidine and the incorporation was measured 16 h later.  
Regardless of genotype, T cells rigorously proliferated in response to CD3/CD28 
stimulation (Fig. 3.6 A). T cells derived from rMT-II+/+ rats but not from WT rats proliferated 
in response to MBP and MBP68-88 in a dose-dependent manner but did not proliferate upon 
stimulation with ovalbumin. Minimal proliferative response (2.5-fold increase over WT) was 
present in rMT-II+/- cells at the maximum concentration of antigen. Of note, the T cell 
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proliferation was abrogated in cultures pretreated with OX-6 antibody blocking the RT1.B 
(rat MHC class II) complex (Fig. 3.6 A).   
Upon stimulation, T cells produce proinflammatory cytokines such as IFNand TNF. LN 
cells were stimulated as described above and supernatants were assayed by ELISA. Here 
again, lymphocytes derived from rMT-II+/+ rats produced IFN in a dose-dependent manner 
but also lymphocytes derived from rMT-II+/- rats produced a substantial amount of IFN 
when challenged with 10 and 100 g/ml MBP (Fig. 3.6 B). TNF could only be detected in 
very low concentrations in the supernatant of stimulated lymphocytes. Production of 
IFNwas also detected by intracellular staining of stimulated lymphocytes. Upon stimulation 
with 100 g/ml MBP, around 20 % of rMT-II+/+ lymphocytes produced IFN(Fig. 3.6 C) but 
not IL-17 (data not shown). Again, the induction of IFN could be completely abrogated by 
application of OX-6 antibody.  
We analyzed mRNA isolated from rMT-II+/+ lymphocytes at different time points after 
stimulation by RT-qPCR. IFN mRNA peaked at 42 h after stimulation with 10 g of MBP 
and a mild increase of TNF mRNA was induced (~1/10 of IFN message). Very low 
amounts of mRNAs of other proinflammatory cytokines, IL-2 and IL-17, were detected at 
30-42 h post stimulation (Fig. 3.5 A). In vitro stimulation of lymphocytes resulted in a rapid 




























































Time after stimulation [h]
Figure 3.5: Kinetic of gene expression in rMT-II
+/+
 lymph node cells stimulated ex vivo. (A) Expression levels of mRNA of the 
cytokines IFN TNF IL-17 and IL-2 and (B) chemokine receptors CXCR3 and CCR7 after stimulation with 10 g/ml of MBP. 
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Figure 3.6: Antigen responsiveness of rMT-II lymphocytes in vitro. (A) Results of [
3
H]-thymidine incorporation assay performed 
in rMT-II and WT lymph node cells stimulated with MBP or MBP68-88 peptide. (B) IFN and TNF production by lymph node cells 
determined by ELISA 48 h after stimulation. (C) Representative intracellular IFN FACS stainings 48 h after lymphocyte 




3.1.1.6 NAÏVE AND MEMORY RMT-II T CELLS IN PERIPHERAL ORGANS 
Mature T cells can be further subdivided into naïve T cells, which did not encounter their 
cognate antigen yet, and memory T cells, which encountered their cognate antigen before 
and are thus able to mount a rapid response to a second antigen encounter. In mice, naïve 
T cells are defined as a CD62Lhigh CD44low population (Sallusto et al., 1999). In rats, CD44 
is highly expressed on both naïve and effector/memory T cells and cannot be used to 
discriminate them, but CD62L (L-selectin) and CD45RC (OX-22) are expressed in naïve rat 
T cells and become down-regulated upon differentiation into effector or memory T cells 
(Bunce and Bell, 1997). 
To further dissect the T cell subtype responsible for proliferation and cytokine production, 
lymphocytes isolated from lymph nodes, spleen and blood were analyzed for their surface 
expression of CD62L (Fig 3.7 A). In lymph nodes and spleen of WT animals around half of 
the CD4+ T cells were CD62L+ whereas around 80 % of the CD4+ T cells in the blood 
expressed CD62L. This distribution was almost equal in homozygous rMT-II+/+ rats. Further, 
CD62L+ and CD62L- T cells were sorted via FACS from lymph nodes of untreated rMT-II+/+ 
rats and their gene expression profile analyzed. 
CD4+ CD62L+ T cells expressed lower levels of CCR2, CCR5 and CXCR3 mRNA 
compared to CD4+ CD62L- T cells (Fig. 3.7 B). However, CCR7 mRNA levels were equal in 
both CD62L+ and CD62L- T cells. mRNA expression levels of Tbet and FoxP3 were higher 
in CD4+ CD62L- T cells. 
T cells were separated for CD62L+ and CD62L- T cell populations via MACS sorting and 
challenged with different concentrations of MBP in vitro to determine the impact of each 
population on T cell proliferation and cytokine production. 
Although CD62L- memory T cells are supposed to provide a rapid immune response upon 
rechallenge with their respective antigen (Ahmed and Gray, 1996; Zinkernagel et al., 1996), 
our data demonstrates that CD62L+ naïve T cells responded stronger to challenge with 
MBP in vitro with regards to proliferation and proinflammatory cytokine production 
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3.1.1.7 rMT-II+/+ T CELLS RESPOND TO THE SPECIFIC ANTIGEN IN VIVO 
Naïve recipients were injected into the hind limbs with splenocytes of rMT-II+/+ rats and 
locally immunized to confirm the antigen responsiveness in vivo.  
To this extent, 5 x 106 lymphocytes were injected into the right hind limb of naïve recipient 
rats. After 16 h, the recipients were immunized with 10 g MBP or 10 g OVA in CFA at the 
same location. T cell numbers were analyzed by cell count of GFP+ cells within the draining 
popliteal lymph nodes three days after immunization. 
As shown in Figure 3.8, in vivo T cell expansion after immunization was stronger upon 





































Figure 3.8: In vivo antigen response of rMT-II
+/+
 
splenocytes. Splenocytes were injected subcutaneously 
and afterwards animals were immunized. Three days after 
immunization with either OVA or MBP in CFA, GFP
+
 cells 
per gram of draining popliteal lymph node were counted 




3.1.2 OVALBUMIN-SPECIFIC TCR TRANSGENIC RATS 
3.1.2.1 CLONING OF AN OVALBUMIN-SPECIFIC TCR  
To clone a Lewis rat TCR recognizing chicken egg ovalbumin protein (OVA), we first 
established an effector T cell line from lymph nodes of a rat immunized with OVA in CFA. 
After one week of primary culture, T cells were restimulated with antigen and 2 days later 
magnetically enriched for cells expressing the TCR-Vß16 chain (Fig 3.9 A). Activated blast 
T cells were then diluted to a clonal density (1 cell per well of a 96-well plate, later called 
clonoids) and cultured in the presence of growth factors. After several rounds of in vitro 
restimulation with ovalbumin, 24 clonoid T cell lines were individually stained for V16-
expression and used for cDNA isolation. Figure 3.9 B shows an exemplary result of FACS 
analysis of three clonoid lines with #15 and #18 positive for V16. Clonoid#15 and #18 
were chosen for detailed sequence analysis. A PCR was performed for the V chain with 
primers annealing in the leader region of the rat V16 gene (Gold et al., 1992) and in the 
constant region of the V chains (Smith et al., 1991). The amplified PCR product was 
sequenced and the following VJ-combinations were deduced: V16-J.4-C1 for clonoid 
#15 and V16-J.3-C1 for clonoid #18 (Fig. 3.9 C). For identification of the -chain, a 
PCR was performed using a set of primers recognizing families of V genes (Buenafe et 
al., 1997) and a reverse primer binding within the constant region of the TCR-chain (Fig. 
3.9 D). The resulting PCR products were sequenced and only the V13-PCR fragment, 
which showed the highest homology to the mouse V15 segment, sequence (V13-J-
C) was in frame for clonoid #15 (Fig. 3.9 E and F) as was V3 for clonoid #18 (V3-J-
C). After this we could design primers to amplify the full-length TCR chains. TCR and 
TCRß coding sequences were then combined with EGFP in a tricistronic cassette and 
inserted into a lentivirus as described earlier for the MBP-specific TCR (Fig. 3.1 C).  
As for the MBP-specific receptor we tested the antigenic response in a TCR-negative 
hybridoma cell line (derived from mouse a BW 58C thymoma line) infected with 
concentrated lentiviral preparation.  Analysis of GFP and surface TCR-V16 expression 
showed that about 20 % of the hybridoma cells expressed both proteins (Fig. 3.9 G). 
Coculture of infected hybridomas with thymic Lewis rat APCs in the presence of antigens 
revealed a dose-dependent induction of mouse IL-2 in response to the specific antigen 
OVA but not to MBP (Fig. 3.9 H). Although both constructs appeared to confer the correct 
specificity, the TCR variant of clonoid #15 might possess a higher affinity as the response 
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was evident at a lower concentration of OVA than for the TCR construct derived from 
clonoid #18. Thus, the TCR construct of clonoid #15 was used for the generation of OVA-
specific TCR transgenic rats. 
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Figure 3.9: Generation and sequencing of OVA-specific T cell clonoids. (A) FACS analysis of polyclonal OVA-specific T cells 
before and after MACS enrichment for V16 (B) FACS analysis of OVA-specific T cell clonoids after expansion from single-cell 
cultures for V16. (C) PCR results for V16 gene expression in different OVA-specific T cell clonoids with the indicated primers. 
(D) PCR results for V-chain gene expression in OVA-specific T cell clonoids #15 and #18 with the indicated primer sets. (E + F) 
Amino acid sequence for V13 and V16of clonoid #15. (G) FACS analysis for GFP and V16 surface expression of lentivirally 
transduced TCR-negative BW 58C hybridoma. (H) Results of mouse IL-2 ELISA assay performed on supernatants from 
hybridoma transduced with TCR#15 and TCR#18 constructs and stimulated with different concentrations of ovalbumin or with 
MBP as a negative control. Graphs depicted as Mean ± SEM. 
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3.1.2.2 ANALYSIS OF rOT-II FOUNDER ANIMALS 
Generation of TCR transgenic Lewis rats was achieved by injecting lentiviral concentrate 
into fertilized Lewis rat oocytes. Embryos which developed into a two-cell stage were 
transferred into pseudopregnant Wistar rat recipients. Rat pups were genotyped and 
phenotyped three weeks after birth. For genotyping, genomic DNA was used as a PCR 
template with primers binding within the P2A sequence and the variable segment of the 
V16 chain (Fig. 3.10 A). FACS analysis of blood cells showed that GFP and the V16-
chain were expressed in peripheral T cells of some founder animals (Fig. 3.10 B). 
Founder animals PCR-positive for integration of the provirus were mated among each other 
and the F1 generation was again phenotyped by analyzing blood lymphocytes three weeks 
after birth. In the F1 generation, all CD4+ T cells expressed GFP and showed an increased 
proportion of V16+ (50-60 % of T cells, data not shown). The new Lewis strain was 
designated as rOT-II standing for rat OVA-specific TCR transgenic MHC class II restricted.  
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Figure 3.10: Founder analysis of OVA-specific TCRtg rats. (A) PCR analysis of genomic tail DNA of founder animals. (B) FACS 
analysis of blood cells from founder animal no. 12 (A), stained with mAb specific for TCR-Vß8.2 and TCR-Vß16 (transgenic 
chain). Data shown in (B) were generated by Dr. Henrike Fischer, Department of Immunology, laboratory of Prof. Holger 





Similar to the rMT-II strain, the levels of GFP- and TCR-V16-expression in the peripheral 
blood T cells and the manner of their inheritance were indicative of wild type (WT), 
heterozygous (rOT-II+/-) and homozygous (rOT-II+/+) genotypes. In contrast to the rMT-II 
strain, we were not able to obtain progenies from pairs of homozygous breeders. Whereas 
rOT-II+/+ males were fertile when crossed to a WT Lewis partner, the fertility of rOT-II+/+ 
females appeared to be compromised, possibly due to a genomic effect of viral integration. 
 
3.1.2.3 EXPRESSION OF GFP AND THE TRANSGENIC TCR IN rOT-II RATS 
Blood, spleens and lymph nodes of WT, rOT-II+/- and rOT-II+/+ rats were analyzed for GFP 
expression. As previously described for rMT-II rats, the GFP expression was higher in 
homozygous rOT-II+/+ rats compared to heterozygous rOT-II+/- rats. Myeloid cells and T cells 
from rOT-II+/+ rats express a higher level of GFP than B cells (Fig. 3.11 A). 
In both rOT-II+/- and rOT-II+/+ animals the percentages of TCR-V16-positive cells were 
significantly increased (Fig. 3.11 B and C). In blood, about 10 % of WT T cells expressed 
the V16-chain. The proportion of TCR-V16+ lymphocytes reached 72 % and 90 % in rOT-
II+/- and rOT-II+/+ rats, respectively (Fig. 3.11 B and C). In lymph nodes, these values were 
12 % for WT, 62 % for rOT-II+/- and 95 % for rOT-II+/+ rats. V16-positive T cells could be 
further divided into a TCRmedium-V16high and a TCRhigh-V16medium fraction (indicated in red 
and purple gates in Fig. 3.11 B). rOT-II+/+ rats showed a strong preponderance of the 
TCRmedium-V16high population. Whereas rOT-II+/- rats still expressed a “endogenous” 
V16high population analogous to the one in WT littermates, rOT-II+/+ rats did not possess 
such a population anymore. In line with this observation, T cells in rOT-II+/- rats still 
expressed other endogenous V chains (V8.5 and V8.2) which were strongly diminished 

























































































 Lewis rats. (B) GFP-expression niveau in lymphocyte subsets of rOT-II
+/+
 Lewis rats.  (C) FACS plots depicting 













 (purple circle). (D) Quantification of V16
+
 T cells in blood 




 rats. (C) and (D) gated on GFP
+
 lymphocytes. n=3 per genotype. Graphs depicted 
as Mean ± SEM. 
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3.1.2.4 T CELL LYMPHOPENIA IN rOT-II RATS 
Analysis of total cell numbers in the thymus and peripheral lymphoid organs showed that 
rOT-II animals were lymphopenic. In the lymph nodes of rOT-II+/- (216 x 106/ g organ) and 
rOT-II+/+ (234 x 106/ g organ) rats cellularity was reduced compared to WT rats 
(586 x 106/ g organ). The same trend could also be observed in thymus and spleen but not 
in blood of rOT-II rats (Fig. 3.12 A).  
FACS analysis of the lymphocyte composition showed a reduced number of T cells in 
lymph nodes (WT 75 %, rOT-II+/- 46 %, rOT-II+/+ 53 %) and a significant reduction in the 
blood (WT 76 %, rOT-II+/- 29 % rOT-II+/+ 27 %) with a reciprocal increase in B cell numbers 
to around 40 % in lymph nodes and 50 % in blood of both rOT-II+/- and rOT-II+/+ rats. This 
manifested itself as a reduction of the T/B cell ratio in both rOT-II+/- and rOT-II+/+ rats 
(Fig. 3.12 B and C). 
To address whether the development of T cells was altered in rOT-II rats, we analyzed 
thymi for the expression of CD4 and CD8 surface markers. A pronounced reduction of 
CD4+ SP thymocytes was found in rOT-II+/- thymus resembling thymic CD4/CD8 pattern of 
rMT-II+/- animals (Fig. 3.12 D and Fig. 3.3 D). This however again did not result in a 
peripheral CD4/CD8 imbalance as 75 % of rOT-II+/- LN T cells were CD4+ (Fig. 3.12 E).  
Thymic development was severely disturbed in rOT-II+/+ rats. This was presented as a 
depletion of CD4+ SP and DP populations with prominent accumulation of thymocytes at 
the DN (up to 50 %) and CD8+ SP stages (25-30 %, Fig. 3.12 D). Unexpectedly, the 
peripheral T cell repertoire in rOT-II+/+ animals was dominated by CD8+ SP cells (70-80 %, 




















































































































































































Figure 3.12: (A) Total cellularity of different lymphoid organs was determined by cell counting. Shown are numbers per g of 
organ or ml of blood in millions of cells. Percentages of GFP
+
 T cells and B cells in lymph nodes (B) and blood (C) determined 
by flow cytometry. (D,E) Representative FACS plots of CD4/CD8 stained cells isolated from the thymus (D) and lymph nodes (E). 
Quantification of CD4/CD8 expressing GFP
+
 lymphocytes depicted on the right. n=3 per genotype. Graphs depicted as Mean ± 




Analysis of the CD4-CD8- DN population of thymocytes revealed that a developmental block 
in rOT-II+/+ thymus is likely to occur at the DN2 stage (CD25+ CD44+, Fig. 3.13 A). Notably, 
a clear expression of the TCR by the majority of DN cells was evident in both rOT-II and 
rMT-II strains (Fig. 3.13 B-C). This however did not result in an obvious DN block in 
developing rMT-II thymocytes (Fig. 3.13 A, see also Fig. 3.3 D).  
Closer analysis of CD8 T cells from lymph nodes of rOT-II+/+ rats indicated that those were 
not a developmentally subverted CD8 population but expressed also a CD8 chain as 






















































Figure 3.13: FACS analysis of aberrant T cell populations in rOT-II
+/+
 host. The CD25/CD44 (A) and TCR (B, C) expression in 




3.1.2.5 REDUCED PROPORTION OF NAÏVE T CELLS IN rOT-II RATS 
To characterize the distribution of naïve and memory rOT-II T cells, lymph node and blood 
cells were stained for the expression of L-selectin (CD62L). 
In CD4+ and in CD8+ T cells of WT rats, the distribution of naïve versus memory T cells was 
similar. In CD4+ T cells of rOT-II+/- and rOT-II+/+ rats this distribution was clearly shifted 
towards CD62L-negative population. More CD62L- T cells were detected among CD8+ rOT-
II+/- T cells as well. More naïve T cells were present in lymph nodes in relation to memory 
CD8+ T cells of rOT-II+/+ rats. Altogether a strong reduction of naïve CD62L+ T cell numbers 























Figure 3.14: Analysis of numbers of naïve T cells in rOT-II strain. Histograms of CD62L surface expression on CD4 and CD8 




 rats compared to WT littermates are shown.  
 
3.1.2.6 NK CELLS AND  T CELLS IN rOT-II ANIMALS 
In line with our observations made in rMT-II rats, expression of the rOT-II transgene had an 
effect on relative numbers of NK and T cells. Both heterozygous and homozygous rOT-II 
rats possessed increased numbers of NK cells in lymph nodes (Fig. 3.15 A) and in the 
blood whereas the number of NK T cells is similar to WT. For rMT-II transgenic rats it was 
shown in Figure 3.4 B that the number of T cells war reduced in both blood and lymph 
nodes. In rOT-II animals, the reduction of T cells in lymph nodes ranges from 1.5 % in WT 











































Figure 3.15: Quantification of FACS analysis for NK cell and T cell markers. (A) Percentage of NK and NK T cells in lymph 




 cells. n=3 per genotype. Data are Mean ± SEM 
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3.1.2.7 rOT-II+/+ T CELLS RESPOND TO OVALBUMIN EX VIVO 
Lymph node cells of rOT-II+/- rats and rOT-II+/+ rats were stimulated with different 
concentrations of OVA protein. We also tested the response to the OVA323-339 peptide, 
which is the immunodominant ovalbumin antigen in Lewis rats. As shown in Figure 3.17 A, 
lymphocytes derived from rOT-II+/+ rats readily proliferated upon OVA protein and  
OVA323-339 challenge in a dose-dependent manner. Proliferation was completely blocked by 
treatment with OX-6 mAb specific for the rat RT1.B complex (MHCII). Additionally, the IFN 
level in the supernatant of stimulated lymphocytes was measured by ELISA and revealed a 
dose-dependent production of IFN in response to OVA (Fig. 3.17 B). Intracellular staining 
of stimulated rOT-II+/+ LN cells demonstrated that roughly 15% of the cells produced IFN 
and other 5% produced IL-17 when stimulated with a high amount of antigen (Fig. 3.17 C 
and D). Production of IFN could be abrogated by OX-6 treatment. 
rOT-II+/+ lymphocytes were challenged with 10 g/ml of OVA and the RNA was isolated at 
different time points to determine the kinetic of the transcriptional response induced by 
antigenic stimulation. This analysis showed a high induction of IFN mRNA that peaked at 
18 h after stimulation. At this time point, maximal level were detected also for TNF and IL-
2 mRNA (Fig. 3.16). In vitro stimulation of lymphocytes resulted in a fast upregulation of 
CXCR3 and CCR7 mRNA – two molecules important for T cell migration - within 6 hours 
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Figure 3.16: Kinetic of transcriptional activation in rOT-II
+/+
 LN T cells. mRNA expression level of proinflammatory cytokines 
IFNIL-17, IL-2 and TNF and chemokine receptors CXCR3 and CCR7 were determined after stimulation with 10 g/ml OVA 







































































































































Figure 3.17: Antigen responsiveness of rOT-II lymphocytes. (A) [
3




 and WT 
lymphocytes stimulated with OVA protein and OVA323-339 peptide measured 48 h after stimulation. (B) IFN production 
determined by ELISA of supernatants form lymphocytes stimulated with OVA for 48 h. (C) Production of IFN and IL-17 by 
stimulated lymphocytes assessed by intracellular staining and flow cytometry. (D) Quantification of cytokine positive cells. 




The majority of T cells in LNs of rOT-II+/+ rats are CD8+ T cells (Fig. 3.12 E). However, the 
proliferation and induction of IFNwas abolished by blocking the MHC class II molecules. 
Thus, the detected antigen response could be mediated solely by a minority of CD4+ rOT-
II+/+ LN cells. To address  the reactivity of CD4+ and CD8+ subsets, we depleted mixed a 
population of LN cells of either CD4+ or CD8+ T lymphocytes by magnetic separation and 
restimulated them with OVA protein. Interestingly, both CD4- and CD8-depleted 
lymphocytes proliferated and produced IFN upon antigen challenge in a dose-dependent 
manner (Fig. 3.18 A and B). CD8-depleted lymphocytes (= CD4+ T cells) reacted to the 
antigen at a lower concentration than CD4-depleted lymphocytes (= CD8+ T cells). 
CD4- or CD8-depleted lymphocytes were subcutaneously injected into the hind limb of 
naïve recipients. 16 h post transfer the recipients were immunzied with either OVA or MBP 
at the same location and 3 days later the in vivo expansion (cell number) of the transferred 
T cells was determined in the draining LNs by flow cytometry. Both CD4- and CD8-depleted 
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 T cell transfer 3 days after immunization in vivo. Graphs depicted as Mean ± SEM.  
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3.2 EAE INDUCTION IN TCR TRANSGENIC RATS 
3.2.1 rMT-II RATS DEVELOPED ACTIVE EAE WITH AN ACCELERATED DISEASE 
ONSET 
rMT-II+/+ rats were observed for a time period longer than one year. The rats did not 
develop EAE spontaneously. Furthermore, we have not found any subclinical T cell or other 
immune cell infiltration into the CNS of transgenic animals by FACS analysis (not shown). 
EAE induction could readily be achieved by immunizing rMT-II rats with 75 g MBP in 
CFA (300 g). All immunized rMT-II+/- and rMT-II+/+ developed EAE with a significantly 
accelerated disease onset (day 6 pi for MT-II+/+ and day 8 pi for rMT-II+/- rats) compared to 
WT littermates (onset at day 10 pi). The disease progression and severity were slightly 
increased compared to WT EAE (Fig. 3.19 A - C). Interestingly, although the majority of 
T cells in rOT-II rats expressed the OVA-specific T cell receptor, the residual non-
transgenic repertoire of rOT-II rats still maintained the capacity to mediate MBP-induced 
EAE. Only 50 % of the rOT-II+/- and 15 % of the rOT-II+/+ rats developed EAE after 
immunization with MBP in CFA however with delayed disease onset (12-13 dpi) comparing 
to WT controls. Nevertheless, the rOT-II rats which did develop the disease presented EAE 
with the same progression and severity as WT controls (Fig. 3.19 D). 
Immunization with OVA in CFA failed to evoke EAE development in any of rMT-II or rOT-II 



















































































































Figure 3.19: Active EAE in TCR transgenic Lewis rats. (A) Percentages of disease-free animals per genotype after active 
immunization with MBP. (B) Average time before onset of clinical EAE for different genotypes. Data are Mean ± SEM. (C) The 
course of active EAE in the rMT strain. (D) EAE disease course in susceptible rOT Lewis rats. n ≥ 7 per genotype. Graphs show  
Mean ± SEM. 
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3.2.2 rMT-II RATS DEVELOPED EAE UPON SUBOPTIMAL IMMUNIZATION  
In order to determine the minimal immune challenge sufficient to induce EAE development, 
we decreased the amount of CFA and immunized rMT-II+/+ rats with MBP (Fig. 3.20 A 
and B). CFA contains heat-inactivating Mycobacterium tuberculosis thus predominantly 
activating the CD4+ T cells with a bias toward a Th1/Th17 response type. 
In rMT-II+/+ rats, 1/5 of the usually used amount of CFA still induced full EAE development. 
Titrating down the CFA concentration showed that 1/20 (15 g CFA) was enough to evoke 
EAE in 75 % of the rMT-II+/+ rats with later disease onset and reduced disease severity but 
no CFA amount lower than 300 g was able to induce EAE in WT rats (WT plots not 
shown). Notably, in this experiment the usual immunization protocol (75 g MBP + 300 g 
CFA) caused the death of all rMT-II+/+ rats in this group. 
As a next step, we analyzed the minimal amount of antigen sufficient to induce EAE. To this 
end, rMT-II+/+ rats were immunized with 75 g, 15g, 7.5g or 0.75g MBP in CFA 
(300g). In this experiment (Fig. 3.20 C), rMT-II+/+ rats immunized with 75 g, 15g and 
7.5g developed severe EAE with a disease onset 5-6 dpi and necessary termination of 
the experiment due to a high clinical score in nearly all immunized rats. However, rMT-II+/+ 
rats immunized with 0.75 g MBP in CFA developed EAE with a slightly delayed disease 
onset (9 dpi) and reduced severity. 
Taken together, the EAE induction results confirm a high responsiveness of the transgenic 
T cells in vivo when challenged with 1 % of the usual amount of cognate but not irrelevant 
antigen in Th1/Th17-favouring adjuvant. However, neither adjuvant in combination with 
irrelevant antigen nor global stimulation of the immune system with LPS could evoke active 
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Figure 3.20: EAE induction in rMT-II
+/+
 Lewis rats with decreased CFA or antigen concentrations. (A) Percentage of disease-free 
animals after immunization with 75 g MBP in combination with 300 g, 60 g or 15 g CFA. n=3 per group. (B) Clinical course 
of EAE induced with reduced amounts of CFA. n=3 per group. Same legend as shown in (A). (C) Clinical course of immunization 
with 300 g CFA and reduced amounts of MBP. In this experiment immunization with 7,5 – 75 g MBP resulted in strong disease 
manifestation with death of the indicated number of animals per group in rMT-II
+/+
 rats but not in (D) WT control animals. n=4 per 
group. Graphs depicted as Mean ± SEM. 
 
3.2.3 SUSCEPTIBILITY OF rMT-II RATS TO A REPEATED IMMUNIZATION 
AND FK506 TREATMENT 
Lewis rats were reported to be resistant to a second immunization with MBP (Sun et al., 
1999). Efficient induction of regulatory T cells upon immunization may be responsible for 
this phenomenon. To test whether rMT-II rats are also resistant to a second disease 
initiation, we immunized heterozygous rMT-II+/- a second time with MBP in CFA 
(Fig. 3.21 A) 10 days after recovery from the first disease bout. 
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In contrast to WT rats, which turned out to be completely resistant to a second 
immunization (red line), the rMT-II+/- cohort developed a mild clinical episode (pink line) 5 
days after the second immunization. This EAE reached a maximum clinical score of 1.5 - 2. 
Naïve WT controls (black line) immunized in parallel using the same preparation of Ag/CFA 
emulsion, developed EAE with classical clinical manifestation starting 10 days after 
immunization. This secondary disease bout could not be explained by a simple lack of 
regulatory T cells (Treg) in the rMT-II pre-immune repertoire, known to occur in some 
TCRtg mice, as the numbers of CD4+CD25+ T cells were only marginally reduced in rMT-
II+/+ rats relative to WT levels (Fig. 3.21 B). 
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Figure 3.21: Differential EAE progression in rMT-II
+/+
 Lewis rats. (A) Disease course of rMT-II
+/-
 rats immunized with MBP for a 
second time 10 days after recovery from the first acute disease bout. n=3 per group. Graphs depicted as Mean ± SEM. (B) FACS 
analysis of LN cells stained for CD4 and CD25 in naïve WT and rMT-II
+/+
 rats. (C) Representative clinical courses of individuals 
with active EAE in rMT-II
+/+
 rats treated with low dose of FK506 or DMSO on every other day. 
 
Treatment with low doses of calcineurin inhibitors cyclosporin A (CsA) or FK506 was 
reported to modify the monophasic course of active Lewis rat EAE to a relapsing or chronic 
progression (Polman et al., 1988; Chelmicka-Schorr et al., 1998). A possible reason of such 
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a conversion could be a selective impact of the treatment on Treg cells, which are 
extremely dependent on IL-2 signaling regulated by calcineurin activity. To test whether this 
also applies to the EAE on the rMT-II background, we immunized rMT-II+/+ animals with a 
low antigen amount (0.75 µg MBP) and treated them every other day with 800 µg of FK506 
per kg of body weight from the day of immunization until the onset of clinical symptoms. 
Remarkably, low-dose FK506 treatment induced a relapsing-remitting disease course in 
rMT-II+/+ rats whereas control transgenic rats treated with DMSO developed a single severe 
disease bout (Fig. 3.21 C).  
 
3.2.4 CLASSICAL IMMUNIZATION IS REQUIRED FOR INDUCTION OF EAE  
IN rMT-II RATS  
To address the question whether the generation of a proinflammatory milieu within CNS 
and a compromising integrity of the blood-brain barrier would suffice to trigger EAE in MBP-
TCRtg hosts, naïve rMT-II+/+ animals were intrathecally injected with LPS combined with 
cognate (MBP) or irrelevant (OVA) antigen. None of experimental conditions resulted in a 
paralytic disease within an observation period of 20 days (Tab. 3.1). Moreover, intrathecal 
transfer of ex vivo pre-activated rMT-II+/+ lymphocytes (exposed to MBP two days before 
injection) did not evoke EAE development (data not shown). We also tried to induce EAE by 
immunizing rMT-II rats with MBP in incomplete Freund’s adjuvant (IFA). This challenge also 
failed to induce clinical EAE development within 20 days of observation (Tab. 3.1). 
 
Table 3.1: The incidence of EAE upon alternative immunization protocols 
 
Genotype Treatment Incidence 
WT 
LPS + MBP i.t. 






LPS + MBP i.t. 






LPS + MBP i.t. 
LPS + OVA i.t. 
0/5 
0/4 
   
WT MPB + IFA s.c. 0/3 
rMT-II
+/-
 MPB + IFA s.c. 0/3 
rMT-II
+/+





3.3 GFP EXPRESSION IN THE CNS OF TCR TRANSGENIC RATS 
Expression of GFP in TCRtg rats is driven by the promoter of the human ubiquitin C gene, 
which is active in a broad range of cell types and tissues. We analyzed the expression 
pattern of GFP within the in the spinal cord of homozygous TCRtg rats by histology. High 
signals of green fluorescence were detected in both meningeal and parenchymal blood 
vessels labelled by intravenously injected red fluorescent dextran (Fig. 3.22).  
A
B TxR-dextran tgGFP Overlay
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Figure 3.22: GFP expression in the spinal cord tissue of rMT-II
+/+
 rats (A) Spinal cord cross-section of rMT-II
+/+
 Lewis rats i.v. 
injected with TexasRed-conjugated 3 kDa dextran 24 h before perfusion analyzed by confocal microscopy. Vascular structures 
(red arrows) and GFP
+
 white matter cells (white arrows) are indicated. (B) 3D-rendered tile scan image of whole-mount 
meningeal surface of lumbal spinal cord of a rMT-II
+/+
 animal stained with DAPI. TxR-dextran is taken up by endothelial cells of 















Figure 3.23: Expression of GFP in glial cells of the spinal cord WM in rMT-II
+/+
 rats. Frozen sections of spinal cord were stained 
with antibodies to Iba1 (A), CNPase (B) and GFAP (C) proteins and analyzed by confocal microscopy. White arrows indicate 
double-positive microglia (A) and oligodendroglia (B) cells. Nuclei were stained by DAPI (shown in blue for overlay images). 
 
In the white matter some resident polymorphic cells resembling oligodendroglia (ODC) were 
also GFPhigh (Fig. 3.22). We stained the tissue for different glial markers (Fig. 3.23) and 
found that Iba1-positive microglia and CNPase-positive ODC express higher level of GFP 
than GFAP-positive astrocytes. 
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In the leptomeninges some perivascular cells also were highly positive for the expression of 
transgenic GFP (Fig. 3.22). To test whether the differential expression of GFP marker in the 
CNS can be used to visualize meningeal structures in intravital imaging settings, spinal 
cords of homozygous rMT-II and rOT-II animals were subjected to TPM analysis (Fig. 3.24). 
In these experiments, the GFP signal clearly delineated endothelial cells of leptomeningeal 
vessels. Moreover, a network of stationary GFP+ cells scanning the microenvironment by 
extension and retraction of cellular processes was present within perivascular and 
intervascular spaces. This behaviour is characteristic for perivascular/meningeal 
macrophages, which are known to originate from bone marrow and possess phagocytotic 
activity. When RFP-tagged bone marrow was transferred into irradiated rOT-II host, RFP+ 
cells were found to populate the meninges of GFP+ host and form a similar pattern as 
putative GFP+ meningeal macrophages do (Fig. 3.24 A).   
In turn, the rOT-II+/+ bone marrow transferred to irradiated WT recipients also gave rise to a 
GFP+ meningeal population with characteristic morphology and distribution (Fig. 3.24 B), 
which could be labelled by intrathecal injection of fluorescent TexasRed-dextran 
(Fig. 3.24 C). This data indicate that GFP expressing cells visualized by TPM in the 
meninges of TCRtg animals are meningeal phagocytes of myeloid origin that are known to 




















Figure 3.24: Transgenic GFP expression highlights meningeal endothelial cells and perivascular macrophages. (A) Selected 
frame of two-photon recording of the spinal cord meninges in a bone marrow chimera rat generated by the transfer of  RFP
+
 
bone marrow  into irradiated rOT-II
+/+
 host. Host meningeal phagocytes indicated by green arrows, donor bone marrow 
originating cells indicated by red arrows. (B) Confocal tile scan image of spinal cord meningeal preparation from rOT-II-BM / WT 
host chimera stained with DAPI. (C) Meninges of BM chimera (B) 24 h after intrathecal injection of TexasRed-dextran stained 







3.4 MIGRATORY PATTERN OF PRIMARY T CELLS IN COMPARISON TO 
EFFECTOR T CELL LINES 
 
3.4.1 EFFECTOR T CELL LINES ESTABLISHED FROM rMT-II+/+ AND rOT-II+/+ RATS 
Effector T cell lines were established from transgenic rMT-II+/+ or rOT-II+/+ hosts. Resting 
rMT-II+/+ and rOT-II+/+ effector T cells were analyzed for GFP, TCR, CD4 and CD62L 
expression and compared to retrovirally engineered WT effector TMBP-GFP or TOVA-GFP 
lines (Flügel et al., 1999). As shown in Figure 3.25 A, rMT-II+/+ effector T cells expressed 
lower levels of GFP and TCR but matched TMBP-GFP effector T cells in the expression 
level of CD4 and the absence of CD62L on the cell surface. Additionally, the transcriptional 
response to antigen challenge in vitro was tested revealing similar expression kinetics of 
proinflammatory cytokine mRNA in rMT-II+/+ effector T cells and TMBP-GFP effector T cells 
(Fig. 3.24 B), although rMT-II+/+ effector T cells produced higher amounts of IFN and lower 
amounts of IL-17 and IL-2 mRNA. CXCR3 and CCR7, chemokine receptors important for 
the entry of T cells into the CNS (Alt et al., 2002; Noor and Wilson, 2012; Schläger, 2013), 
were regulated following a similar kinetic in rMT-II+/+ effector and TMBP-GFP effector T cells. 
In effector rOT-II+/+ T cells, the GFP and TCR levels were lower compared to TOVA-GFP 
T cells and showed the same amount of CD62L (Fig. 3.25 C). However, rOT-II+/+ T cells 
also exhibited a slightly lower expression level of the CD4 coreceptor. Given that donor 
rOT-II+/+ rats possessed a higher number of CD8+ T cells before immunization, these data 
suggest that the immunization protocol and ex vivo culturing favour the propagation of 
CD4+ T cells.  
The kinetic of antigen-induced mRNA expression of proinflammatory cytokines IFN, IL-17, 
IL-2 and TNF as well as the expression levels of CXCR3 and CCR7 in rOT-II+/+ effector T 

























































Time after stimulation [h] 
WT TMBP-GFP effector T cells














































rOT-II+/+ effector T cells




























Time after stimulation [h] 
WT TOVA-GFP effector T cells
 
Figure 3.25: In vitro characterization of effector T cell lines. (A) Surface expression of GFP, TCR, CD4 and CD62L in a 
conventional TMBP-GFP (grey/black) and a rMT-II
+/+
 effector T cell line (red) assessed by flow cytometry. (B) Comparison of 
changes in mRNA expression of proinflammatory cytokines and chemokine receptors in response to in vitro stimulation with 
10 g/ml MBP. (C) Surface expression of GFP, TCR, CD4 and CD62L in a conventional TOVA-GFP (grey) and a rOT-II
+/+
 effector 
T cell line (blue) assessed by flow cytometry. (D) mRNA expression kinetics of proinflammatory cytokines and chemokine 
receptors after in vitro stimulation of  rOT-II
+/+
 effector T cells with 10 g/ml OVA. (B, D) Data shows relative expression levels 
normalized to ß-actin message. 
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Figure 3.26: The course of EAE induced by adoptive transfer of rMT-II
+/+
 effector T cell lines, WT TMBP-GFP T cells or isolated 
naïve lymphocytes activated in vitro for two days with concanavalin A (ConA) or MBP. GFP
retro
, effector T cell line transduced 
with GFP-retrovirus. n = 3 per group. Graphs depicted as Mean ± SEM. 
 
Two effector T cell lines derived from rMT-II+/+ rats with or without additional retroviral 
transduction of GFP were intravenously transferred into naïve recipients (5 * 106 T 
cells/recipient, Fig. 3.26).  
Both the rMT-II+/+ effector T cell line and the GFP-transduced rMT-II+/+ effector T cells 
(GFPretro) induced fulminant EAE development with a disease onset 2 – 2.5 days after 
transfer. Animals did not only develop conventional EAE symptoms but also atypical 
neurological symptoms like hyperesthesia, tremor and partial tetraparesis. Pronounced 
front limb weakness developed before the onset of a complete hind limb paralysis. Due to 
the strong disease manifestation, most of the experiments had to be terminated at the peak 
of the disease. In comparison, WT TMBP-GFP cells induced typical adoptive transfer EAE 
reported earlier (Flügel et al., 1999). 
To assess whether also naïve rMT-II+/+ lymph node cells briefly primed in vitro inherit the 
capability to induce EAE, lymph node cells were taken into culture (without prior 
immunization) and either unspecifically stimulated with concanavalin A (1 g/ml) or 
specifically with MBP (10 g/ml). On day 2 after stimulation, T cells were transferred 
intravenously into naïve recipients but did not evoke clinical EAE. 
The atypical neurological symptoms observed after transfer of rMT-II+/+ effector T cells 
hinted not only of a T cell infiltration into the spinal cord but also regions of the brain.  
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GFP+ T cell numbers in spinal cord and brain regions were assessed via FACS analysis as 
before. Numbers of T cells infiltrating the lumbal and cervical spinal cord at the peak of the 
disease were comparable in recipients of rMT-II+/+ and WT TMBP-GFP effector cell lines. 
However, more GFP+ T cells infiltrating cerebrum and cerebellum were found in recipients 
of rMT-II+/+ effector T cellss (Fig. 3.27 A).  
Immunohistochemical analysis for activation of microglia/macrophage infiltration by 
immunostaining for Iba-1 and CD68 (ED1) showed stronger signals for Iba-1 and ED1 
expression in cerebellum and cerebrum in brain sections from rMT-II+/+ effector T cell 
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Figure 3.27: Analysis of brain regions in adoptive transfer EAE of rMT-II
+/+
 effector T cell lines at the peak of the disease. (A) 
GFP
+
 cells per gram organ in different CNS compartments after adoptive rMT-II
+/+
 effector and TMBP-GFP T cell transfer. n = 1 per 




3.4.3 TRANSFER OF SPLENIC rMT-II+/+ CELLS BEFORE IMMUNIZATION 
ACCELERATES THE ONSET OF ACTIVE EAE 
As GFP is expressed under control of the ubiquitin promoter, not only T cells but also many 
other cell types in TCRtg rats express this fluorescent marker (e.g. Fig. 3.22). To 
circumvent this inconvenience, splenocytes of untreated rOT-II+/+ or rMT-II+/+ rats were s.c. 
transferred into the hind limbs of naïve WT recipients. Many of these T cells seem to 
migrate to the draining LN and accumulate there. 16 hours post transfer recipients were 
s.c. immunized with MBP antigen in CFA at the same location where T cells were injected.  
This enables analysis of early activation events of T cells in the draining popliteal LNs and 
their migratory routes. 
In this setup, rats receiving rMT-II+/+ splenocytes developed EAE 6 days post immunization 
whereas recipients receiving rOT-II+/+ splenocytes developed EAE 11 dpi as did WT rats 
not receiving any cell supplementation (Fig. 3.28 B, WT EAE plot is not shown). Disease 
duration and severity were not altered. Additionally, even heterozygous rMT-II+/- cells could 
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 with subsequent immunization of MBP. (B) EAE curve after local transfer and activation of 
effector T cells derived from rMT-II
+/+




Interestingly, subcutaneous transfer of an effector T cell line derived from rMT-II+/+ rats with 
subsequent immunization could further accelerated the disease onset (4 days post 
immunization) but neither alter the disease duration nor the severity (Fig. 3.27 B). 
 
3.4.4 MIGRATORY PATTERN OF SPLENIC rMT-II+/+ CELLS AND EFFECTOR rMT-II+/+ 
T CELLS AFTER LOCAL ACTIVATION IN LYMPH NODES 
To follow the migratory route of rMT-II+/+ splenocytes or effector T cells derived from rMT-
II+/+ animals, either cell type was injected into the right hind limb of naïve recipients. 
Animals were immunized at the same location and expansion and the migratory route of 
T cells were monitored by assessing the GFP+ cell number in distinct organs. 
Splenic T cells first expanded in the draining popliteal lymph node with a peak 4 days after 
immunization (Fig. 3.30 A). The expanded GFP+ cells were further characterized by FACS 
analysis showing that all GFP+ cells expressed CD4 and additionally CD8, which can here 
be used as a marker for T cell activation (Fig. 3.29 A, Kenny et al., 2004). The transferred 
splenocytes also contained B cells and macrophages. However, FACS analysis could show 
that only T cells entered the draining lymph nodes and expanded (Fig. 3.29 A) after transfer 
and during the whole kinetic GFP+ cells were always TCR+. 
Three days after immunization, T cells appeared in blood, spleen (Fig. 3.30 A) and other 
lymph nodes (data not shown) before entering the meninges and the CNS parenchyma 5-6 
dpi. The cells were also detectable in both meninges and CNS parenchyma 7 days after 
immunization when animals reached the peak of the disease and some cells still circulated 
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Figure 3.29: FACS analysis of TCR, CD4 and CD8 expression on transferred splenic (A) and effector (B) rMT-II
+/+
 T cells 
before and after activation in draining lymph nodes (dLN).  
 
Effector rMT-II+/+ T cells followed a similar migratory route to the CNS with a rapid 
expansion in the draining lymph node peaking already two days after immunization. All 
GFP+ cells were T cells and expressed CD4 in draining lymph nodes 3 days post 
immunization (Fig. 3.29 B). 
On day 3 the T cells appeared in blood (Fig. 3.30 B) and 1 day later, during the onset of 
disease, were detectable in spleen, meninges and CNS parenchyma. However, at the peak 
of the disease nearly no GFP+ T cells were detectable in blood, meninges and CNS 
parenchyma. 
All in all, the maximum total cell number of GFP+ cells in all organs except CNS 
parenchyma of rats transferred with splenic T cells was reduced 10-fold for peripheral 
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 cells per gram or ml organ in million cells counted by FACS analysis after transfer of splenic rMT-II
+/+
 (A) and 
effector (B) rMT-II
+/+
 cells at the indicated days after immunization. n ≥ 3 per day. Graphs depicted as single values (black dots) 
and mean (red line). 
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3.4.5 rMT-II+/+ T CELLS BECOME REACTIVATED IN THE CNS AND PRODUCE 
PROINFLAMMATORY CYTOKINES 
To analyse the activation status of transferred T cells along their migratory route, cell 
suspensions of different organs at different time points were stained for FACS analysis with 
an anti-CD25 antibody. CD25, the -chain of the IL-2 receptor, could be used as a marker 
for activation as it is upregulated on the T cell surface after antigen recognition. 
As shown in Fig. 3.31 A, both splenic GFP+ T cells as well as effector T cells expressed 
basal levels of CD25 on the cell surface before subcutaneous transfer and before 
immunization with MBP. Effector T cells already showed an enhanced basal expression of 
CD25. However, analysis of the CNS at the EAE onset revealed an accelerated CD25 
surface expression of splenic and effector T cells in meninges and CNS parenchyma 
confirming a reactivation of both T cell populations within the target tissue. 
This observation could be confirmed by dissecting the gene expression of proinflammatory 
cytokines of the transferred T cells. To this extent, GFP+ cells were sorted from various 
organs at different timepoints and mRNA expression levels were analyzed via qPCR 
(Fig. 3.31 B).  
Splenic T cells upregulated IFN mRNA one day after immunization. Circulating T cells in 
the blood during the onset of the disease did not express IFN mRNA but the number of 
transcripts increased drastically within T cells isolated from CNS meninges and 
parenchyma at the disease onset. T cells recovered from the CNS compartments at the 
disease onset also expressed IL-17 and TNF mRNA. While TNF mRNA was still 
expressed at high levels during the peak of the disease in the CNS compartments, 
expression levels of IFN and IL-17 mRNA dropped drastically. Interestingly, we observed 
upregulated IFN expression in T cells recovered from the blood during the peak of the 
disease indicating that there might by a subpopulation of T cells leaving the CNS meninges 
or parenchyma after local reactivation. 
In comparison to splenic T cells, effector T cells sorted from the different compartments 
expressed 4-10-fold higher levels of proinflammatory cytokine mRNA (Fig. 3.31 C). In 
detail, we observed an upregulation not only of IFN but also of IL-17 and TNF within the 
popliteal lymph node one and three days post immunization. At the disease onset, IFN and 
TNF mRNA was detectable in the blood and - in addition to IL-17 mRNA - in CNS 
meninges and parenchyma. At the peak of the disease, IFN and IL-17 as well as TNF 
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mRNA levels dropped drastically. There was no proinflammatory cytokine mRNA 
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Figure 3.31: Analysis of splenic rMT-II
+/+
 and effector rMT-II
+/+
 T cells during EAE. (A) Representative FACS histogram of CD25 
surface expression of GFP
+
 T cells at different time points during EAE development. Representative plots of mRNA expression 
level normalized to -actin of proinflammatory cytokines during EAE development from sorted GFP
+
 cells after splenic rMT-II
+/+
 
(B) and effector rMT-II
+/+






3.4.6 INTRAVASCULAR CRAWLING AT THE BLOOD-BRAIN BARRIER DISTINGUISHES 
EFFECTOR FROM SPLENIC rMT-II+/+ T CELLS 
Conventional TMBP-GFP effector T cells are known to crawl along the endothelium of 
leptomeningel blood vessels before transmigrating into the CNS parenchyma 
(Bartholomaus et al., 2009). 
When analyzing the migratory behaviour of rMT-II+/+ derived effector T cells 48 h (before 
disease onset) after intravenous transfer via two-photon live microscopy we could observe 
a certain fraction of cells crawling intraluminally along the vessel endothelium (Fig 3.32 B).  
However, splenic rMT-II+/+ T cells transferred subcutaneously and activated locally did not 
show this intraluminal crawling phenotype before disease onset (Fig. 3.32 A).  
A
B
Splenic rMT-II+/+ T cells
Effector rMT-II+/+ T cells
Score 0
day 1 p.t. day 1 p.t.
T cell tracks:    Intralumnial Extravasated
Score 0
Score 0 Score 0 Score 0
day 1.5 p.t.
GFP+ T cells TexasRed-dextran (vessels)  Collagen
 
Figure 3.32: Two-photon live microscopy analysis of T cells invading leptomeninges of the spinal cord during atEAE. (A) First 
rMT-II
+/+
 T cells after priming in the popliteal lymph node appeared in the CNS meninges 4 days after immunization (arrows). 
Massive T cell infiltration before clinical manifestation could be observed 5 days after immunization. T cells do not crawl within 





 effector T cells. Already 24 h after transfer first T cells with intraluminally crawling (yellow tracks) and few extravasated 
ones (white tracks) can be seen.  
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As chemokine receptors such as CXCR3 and CCR5 are thought to be key mediatiors in the 
crawling and transmigration process of T cells through the blood-brain barrier (Schläger, 
2013) we sorted GFP+ T cells from different organs and analyzed their chemokine receptor 
expression pattern.  
In both splenic and effector T cells an upregulation of CXCR3 mRNA was observed in 
blood, CNS meninges and CNS parenchyma during EAE onset although with a higher 
expression level in effector T cells (Fig. 3.33 A and B). Effector T cells further expressed 
CXCR3 mRNA during the peak of disease. CCR5 was only detectable in effector T cells 
sorted from blood, CNS meninges and parenchyma during the disease onset. Effector T 
cells expressed CCR2 mRNA, a molecule involved in the recruitment of T cells to 
inflammatory sites, at higher levels than splenic T cells.  
Splenic T cells expressed CCR7, a chemokine receptor either expressed on naïve or 
effector-memory T cells, during the disease onset in blood and in blood and meninges at 
the peak of the disease. Interestingly, the splenic T cell population which could be 
recovered from blood during the peak of disease expressed CCR2, CCR7 and CXCR3 
mRNA. 
Taken together, these results showed a differential chemokine receptor expression pattern 
in splenic T cells and effector T cells entering the CNS compartment during the onset of 
EAE. As especially CXCR3 and CCR5 are associated with a crawling phenotype of T cells 
along the endothelium of blood vessels, the lower expression level or absence of 
expression could explain the lack of crawling observed in splenic T cells with two-photon 
microscopy. 
Additionally, the expression of CCR2, CCR7 and CXCR3 recovered from blood as well as 
the expression of CCR7 within CNS tissues during the peak of the disease hint at a 
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Figure 3.33: Analysis of splenic rMT-II
+/+
 and effector rMT-II
+/+
 T cells during EAE. Representative plots of mRNA expression 
level of chemokine receptors during EAE development from sorted GFP
+
 cells after splenic rMT-II
+/+
 (A) and effector rMT-II
+/+
 




3.4.7 SPLENIC rMT-II+/+ T CELLS CAN DEVELOP INTO CENTRAL-MEMORY T CELLS 
As an additional read-out for T cell activation, cell suspensions were stained for CD62L 
surface expression which is expressed on naïve T cells and central-memory T cells (TCM) 
and down-regulated after activation and completely absent on effector T cells. 
Before transfer, around 40 % of the transferred splenic rMT-II+/+ T cells expressed CD62L. 
In the GFP+ T cells, CD62L expression was downregulated on day 3 after immunization 
suggesting that splenic rMT-II+/+ T cells were completely activated by the immunization 
(Fig. 3.34 A). However, a small fraction of circulating splenic rMT-II+/+ T cells in the blood 
one day before the disease onset expressed CD62L but none of the splenic rMT-II+/+ T cells 
observed in CNS parenchyma at the disease onset. Additionally, circulating effector  
rMT-II+/+ T cells in the blood before the disease onset did not express CD62L.  
As both naïve and TCM T cells express CD62L, we were interested in determining the 
phenotype of this cell population in more detail. GFP+ CD62L+ or CD62L- T cells as well as 
endogenous CD62L+ or CD62L- T cells were sorted from the blood before the disease 
onset and analyzed for the gene expression of proinflammatory cytokines IFN and TNF, 
chemokine receptors CCR2, CCR5 and CCR7.  
GFP+ CD62L+ T cells expressed higher levels of IFN and TNFmRNA compared to 
endogenous CD62L+ T cells. Furthermore, GFP+ T cells and endogenous T cells featured 
the same expression pattern of chemokine receptors with CD62L- T cells expressing higher 
levels of CCR2 and CCR5 compared to CD62L+ T cells. However, both GFP+ and 
endogenous CD62L+ T cells expressed more CCR7 mRNA than CD62L- T cells 

































































































Figure 3.34: Analysis of a CD62L
+
 T cell population circulating in the blood. (A) Histogram overlays of CD62L surface 
expression in the periphery and CNS at different time points during EAE development. (B) Representative mRNA expression 
plots of sorted adoptively transferred GFP
+











3.4.8 MIGRATORY PATTERN OF SPLENIC rOT-II+/+ CELLS AND EFFECTOR rOT-II+/+ 
T CELLS AFTER LOCAL ACTIVATION 
As the migratory route we observed for rMT-II+/+ after subcutaneous transfer and activation 
might be a T cell intrinsic migratory program not restricted to autoimmune T cells, we 
transferred rOT-II+/+ splenocytes or effector T cells derived from rOT-II+/+ animals and 
immunized recipients locally with OVA in CFA. The migratory route was monitored by 
assessing the GFP+ cell number in distinct organs. 
Splenic T cells first expanded in the draining popliteal lymph node with a peak 3-4 days 
after immunization (Fig. 3.35 A). Three - four days after immunization, T cells appeared in 
blood, spleen (Fig. 3.35 A) and other lymph nodes (plots not shown). As there was no 
target antigen present for these T cells in the CNS, there was no inflammation and the cells 
could not be detected in the CNS or meninges (plots not shown). 
Effector rOT-II+/+ T cells followed a similar migratory route with a rapid expansion in the 
draining lymph node peaking 3-4 days after immunization. On day 3 the T cells appeared in 
blood (Fig. 3.35 B) and spleen but again did not enter meninges and CNS parenchyma.   
All in all, the maximum total cell number of GFP+ cells in all organs was reduced 10-fold for 
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 cells per gram organ after transfer of splenic rOT-II
+/+
 (A, n ≥ 3 per day) and effector (B, n = 2 per day) rOT-II
+/+
 T 
cells at the indicated days after immunization. Graphs depicted as single values (black dots) and mean (blue line). 
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3.4.9 GENE EXPRESSION PROFILE OF SPLENIC rOT-II+/+ CELLS AND EFFECTOR rOT-
II+/+ T CELLS AFTER LOCAL ACTIVATION 
Elucidating the chemokine receptor mRNA expression levels, both splenic and effector 
T cells upregulated CCR2 and CXCR3 mRNA in T cells sorted from blood circulation  
5-7 days after immunization with an approximately 10-fold higher expression level in 
effector T cells (Fig. 3.36). CCR5 was only detectable in splenic T cells sorted from blood 
and effector T cells obtained from the draining popliteal lymph node at indicated time 
points. Splenic T cells expressed CCR7 during their expansion in the draining lymph node 
as well as during blood circulation 5 and 7 days after immunization. At day 7 after 
immunization, effector T cells recovered from the blood did also express CCR7. 
Taken together, these results showed a differential chemokine receptor expression pattern 
in splenic T cells and effector T cells circulating in the blood at time points when 
encephalitogenic T cells would potentially cause EAE. At this point of observation, the 
mRNA expression pattern again hints at a heterogeneity of T cell subpopulations which 
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Figure 3.36: Analysis of splenic rOT-II
+/+
 and effector rOT-II
+/+
 T cells after local activation. Representative plots of mRNA 
expression level of chemokine receptors CCR2, CCR5, CCR7 and CXCR3 during EAE development from sorted GFP
+
 cells after 
splenic rOT-II
+/+
 and effector rOT-II
+/+





Lewis rat EAE is a classical model for studying acute inflammatory pathomechanisms in the 
CNS. The adoptive transfer of MBP-specific CD4+ effector T cells cultured ex vivo induces 
a monophasic paralytic disease. Because effector T cells can be genetically manipulated 
ex vivo to express fluorescent markers, adoptive transfer EAE is a well suited method for 
intravital imaging of autoreactive and non-pathogenic T cells in CNS tissue. Such an 
analysis however is limited to an effector Th1 CD4+ T cell population; its behavior may also 
be biased by prolonged ex vivo culturing with multiple restimulation cycles. We aimed to 
provide the Lewis rat EAE model with new experimental modalities, for example an access 
to naïve T cells of defined specificity. This can be achieved by generating TCR transgenic 
animals which have proven to be a powerful approach for providing useful tools for 
immunological and CNS autoimmunity research (Goverman et al., 1993; Lafaille et al., 
1994; Bettelli et al., 2003). The first aim of this study was therefore the generation and 
characterization of TCR transgenic Lewis rats. Secondly, we wanted to investigate the 
migratory behaviour of naïve antigen-specific T cells upon in vivo priming and in the course 
of EAE. 
 
4.1 GENERATION AND INITIAL ANALYSIS OF TCR TRANSGENIC RATS 
4.1.1 MBP-SPECIFIC TCR TRANSGENIC RATS 
We used the previously established effector T cell line Z85 (Chluba et al., 1989) with 
characterized composition of the TCRß chain - utilizing the Vß8.2 segment detectable by 
mAb R73 (Torres-Nagel et al., 1993) - to reconstruct a MBP-specific TCR. This receptor 
was reported to recognize myelin self-antigen presented by Lewis rat MHC class II 
molecules. As the Z85 line was established from a normal T cell repertoire of a Lewis rat, 
the thymocytes harbouring this TCR would presumably be able to escape negative 
selection against self-reactive clones during development and be eventually present in the 
peripheral immune system of transgenic animals. We were able to identify a TCR chain 
that, upon combination with the Z85 TCRß chain and subsequent viral transfer into 
receptor-negative hybridoma, confers surface expression of a functional ßTCR. This 
receptor mediated a response to MBP presented by Lewis rat APCs (Fig. 3.1 D-E).  
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High-titer lentiviruses carrying genes for one fluorescent marker and two TCR chains were 
prepared and used for transduction of early Lewis rat embryos. Although several founders 
with genomic integration of the provirus were identified, only few of them exhibited GFP 
expression in blood cells. Further breeding resulted in animals which expressed GFP 
marker, albeit at different levels, in all peripheral blood leukocytes and displayed a high 
proportion of mature T cells expressing the TCR-V8.2 chain. This phenotype seems to be 
stably inherited through several generations in a new Lewis strain which has been 
designated rMT-II. The levels of GFP expression and their inheritance suggest that a single 
chromosomal integration site (one allele) is present in rMT-II rats. Importantly, rMT-II+/+ and 
rMT-II+/- genotypes which can be deduced from GFP expression associate with quite 
distinct properties of the mature T cell repertoire (Fig 3.3). In mice, a monoallelic expression 
of the transgenic TCR is usually enough to cause allelic exclusion of  chain expression 
and minimize the number of T cells expressing endogenously rearranged TCR genes 
distinct from the transgenic TCR. In rMT-II+/- rats, allelic exclusion is not very efficient. It is 
tempting to speculate that the TCRhigh-V8.2medium population of T cells (Fig. 3.2 C, similar 
also in Fig. 3.11 B for rOT-II+/- TCRhigh-V16medium) may express two different TCRs – one 
transgenic and another endogenous, e.g. V8.5 or V16. This possibility has to be 
addressed by further analysis.   
The reason for inefficient allelic exclusion could be a suboptimal transcription rate driven by 
the ubiquitin promoter in rat T cells. Two observations argue in favour of this explanation. 
First, in rOT-II heterozygotes (discussed below) where TCR transcription is driven by the 
same promoter, allelic exclusion is also inefficient. Second, mean levels of TCR (and 
CD3) expression in homozygous rMT-II and rOT-II T cells is lower than in WT T cells. 
Hence, it is rather the nature of the lentiviral promoter than an effect of the integration site 
that mediates the lack of allelic exclusion. Furthermore, even in rMT-II+/+ T cells the 
expression of GFP is only of a moderate level, i.e. several fold lower than the expression 
achieved by retroviral transduction of T cells (Flügel et al., 1999). This level is fully sufficient 
for FACS analyses and confocal microscopy, but for intravital imaging the introduction of 
additional bright fluorescent markers would be an advantage. It should be noted, that the 
rMT-II strain can be maintained on a homozygous background, which is not the case for 
several other transgenic rat strains, e.g. rOT-II or AsRed (RFPtg). 
rMT-II+/+ T cells challenged with antigen in vitro responded by proliferation and production 
of proinflammatory cytokines in a dose-dependent manner, thus confirming both the 
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functionality and the specificity of the receptor (Fig. 3.6). The blocking of TCR interaction 
with MHC class II complex by the monoclonal OX-6 antibody completely prevented 
proliferation and cytokine production and confirmed the MHC class II restriction of the TCR 
(Fig. 3.6). 
Collectively, initial phenotyping of rMT-II animals indicated that lentiviral transgenesis is a 
suitable approach for the generation of TCRtg rats with pre-determined antigenic specificity 
including self-antigens.  
 
4.1.1.1 CHARACTERISATION OF THE T CELL COMPARTMENT IN rMT-II RATS 
As expected, the proportion of CD8+ T cells in the periphery of rMT-II+/+ animals is reduced 
due to an expanded CD4+ population, which is in line with MHC class II restriction of the 
transgenic TCR. This also suggests that our transgenic self-reactive TCR is spared by 
negative selection in the thymus. The preferential commitment to  T cell lineage due to 
early expression of the transgenic TCR is a likely reason for reduced number ofT cells 
(also in the rOT-II strain). In the LN and spleen of rMT-II+/+ rats roughly half of the T cells 
expressed L-selectin (CD62L), a marker of naïve lymphocytes. The abundance of CD62L+ 
T cells was similar between WT and MBP-TCRtg animals. Furthermore, CD45RC, another 
marker for naïve rat T cells, was present in a similar proportion of T cells as CD62L (data 
not shown). Sorting out CD62L+ and CD62L- T cells by flow cytometry and analyzing their 
gene expression revealed higher levels of CCR2, CCR5 and CXCR3 mRNA in CD62L- 
T cells (Fig. 3.7 A, B). Expression of these chemokine receptors which are important for 
infiltration of inflamed tissues would be more appropriate in the memory subset, as memory 
T cells are considered to be equipped with a molecular repertoire that rapidly hoists an 
immune response upon antigen challenge. Interestingly, CCR7, a chemokine receptor 
usually used as a marker for naïve T cells, was expressed on the mRNA level to the same 
degree in CD62L+ and CD62L- T cells sorted from rMT-II+/+ rats. In 2005, Unsoeld and 
Pircher reported a similar observation as they described three distinct memory T cell 
subtypes (Unsoeld and Pircher, 2005): CD62L+ CCR7+, CD62L- CCR7- and CD62L- 
CCR7+. CD62L+ CCR7+ memory T cells were classified as central-memory T cells (TCM) 
and CD62L- CCR7- as effector-memory T cells (TEM). CD62L
- CCR7+ memory T cells were 
subsequently described as intermediate memory T cells (T IM). Furthermore in rMT-II
+/+ 
animals,  not stimulated CD62L- T cells expressed higher mRNA levels of Tbet and FoxP3 
94 
 
transcription factors, characteristic for antigen-experienced cells. Thus, CD62L+ T cells 
found in LNs and spleen of rMT-II rats are likely to be naïve MBP-specific T lymphocytes.     
Surprisingly, when stimulated with MBP (Fig. 3.7 C, D), CD62L+ T cells proliferated even 
stronger than CD62L- T cells (Fig 3.7 C). This observation was quite unexpected as CD62L- 
memory T cells are reported to be more rapidly responsive upon antigen challenge. 
Increased responsiveness of the “naïve” CD62L+ T cell pool might indicate a presence of 
CD62L+ memory T cells (TCM). Nevertheless, the kinetic of activation of splenic rMT-II
+/+ 
cells (where ~50 % are CD62L+) in vitro shows that maximal expression of IFN occurs 
relatively late –  at 42 h after stimulation (Fig 3.5 A).  Activation of rOT-II+/+ cells (discussed 
later; ~5 % are CD62L+) appears to proceed faster with a maximum of IFNdetected at 
18 h post stimulation (Fig. 3.16). Effector rMT-II+/+ cells which are uniformly CD62L- show 
maximal mRNA level of IFN already at 8 h post stimulation (Fig. 3.25 B). These data 
indicate that the proportion of CD62L+ T lymphocytes in a given population reflects the 
number of true naïve cells and determines the kinetic (rapidity) of T cell response to the 
antigen.  
In the future, it will be important to assess the utility of the CD45RC, CD27 and CD28 
markers to discriminate naïve and memory T cell subsets in TCRtg rats (Okada et al., 
2008; Bunce and Bell, 1997) and to determine the distribution of naïve versus memory 
phenotypes in younger rMT-II animals. 
 
4.1.2 OVA-SPECIFIC TCR TRANSGENIC RATS 
Our experience with rMT-II rats indicated that the availability of the mAb for detecting a 
TCRß chain of the transgenic receptor is of significant advantage for later analyses. 
Therefore, we used the HIS-42 mAb to enrich a polyclonal OVA-specific Lewis T cell line for 
TCR-Vß16-positive cells. Further, we used limiting dilution and sequential restimulation in 
culture to obtain clonal T cell lines (called clonoids; Fig. 3.9 A, B). In this way, we were able 
to clone a handful of TCR candidates without performing the procedure of cell fusion and 
screening of hybridomas. After testing expression and antigenic specificity, we selected one 
TCR (V13-J-CandV16-J.3-C1) for the generation of transgenic rats. Lentiviral 
transduction of embryos yielded a number of founder rats in which the integration of the 
provirus was identified by PCR analysis. In few of those animals only a small fraction of 
blood leukocytes exhibited expression of GFP. Breeding of GFP+ founders resulted in 
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animals which expressed either high, moderate or no GFP levels. As in case of the rMT-II 
strain, the rOT-II allele was inherited according to Mendelian rule and the GFP expression 
level correlated with abundance of peripheral T cells expressing the TCR-Vß16 chain.  
Homozygous rOT-II+/+ rats had ~90 % of V16+ T cells in the blood and secondary lymphoid 
organs (Fig. 3.11 B). Accordingly, strong proliferation and induction of IFN in response to 
ovalbumin protein and OVA323-339 peptide substantiate the engineered antigen–specificity of 
rOT-II animals (Fig. 3.17). 
 
4.1.2.1 IMPAIRED T CELL DEVELOPMENT IN rOT-II+/+ THYMUS  
In contrast to rMT-II rats, rOT-II animals presented themselves as moderately lymphopenic. 
Further analysis of the immune system uncovered a severe disturbance of T cell 
development (Fig. 3.12). In the rOT-II+/+ thymus, an abnormal increase in CD8 SP and DN 
and a reduction of DP and CD4 SP populations were found. 
T cell progenitors enter the thymus in a state when CD4 and CD8 molecules are not yet 
expressed. These cells are then regarded as DN thymocytes. According to the surface 
expression of CD44 and CD25 molecules, DN thymocytes can be further divided into  
DN1-DN4 subpopulations. During the transition throughout DN stages, T cells undergo  
-selection. In this process, the TCR -chain pairs with an invariant pre-T chain. If the  
-checkpoint generates positive signal(s), thymocytes proliferate and transit to the DP 
stage.  
Defects in T cell development were already reported for some TCRtg mice  
(Kisielow et al., 1988; Barnden et al., 1998; Lacorazza et al., 2001). The early  
co-overexpression of the transgenic -chain and -chain in TCRtg mice impairs -selection 
as the affinity for -chain--chain pairing is higher than -chain-preT chain pairing  
(Trop et al., 2000). This drastically reduces the ability of TCR transgenic thymocytes to 
undergo -selection (Borowski et al., 2004). Baldwin et al. could show that the timing of  
-chain expression is indeed critical for thymocyte development and T cell selection 
processes (Baldwin et al., 2005).  
Analysis of the DN population in rOT-II+/+ rats revealed a prominent accumulation of cells at 
the DN2 stage (Fig. 3.13 A). The expression of the TCR was indeed high in DN 
thymocytes of rOT-II+/+ rats (Fig. 3.13 B). This fact of premature expression of the -chain 
is unlikely to be solely responsible for the DN2 block, as a similar expression was also 
96 
 
detected in rMT-II+/+ thymocytes at the DN stage (Fig. 3.13 C), which however did not 
manifest in disturbed DN to DP transition.   
Additionally, rOT-II+/+ thymocytes accumulated in the CD8 SP stage. This might also be 
caused by a lack of signalling as DN thymocytes first upregulate CD8 and then CD4 for 
transition to the DP stage. Signals necessary to upregulate CD4 might also be hampered 
as upregulation of coreceptors is linked to the -chain locus rearrangement  
(Starr et al., 2003; Hernandez-Munain et al., 1999). Another possible explanation might be 
the high affinity of the cloned OVA-specific T cell receptor. Due to this high affinity, CD4+ 
T cells strongly interacting with MHC class II molecules might be deleted from the 
repertoire enabling predominantly CD8+ T cells (expressing a “wrong” coreceptor) to 
interact with a lower affinity with MHC class II (Tyznik et al., 2004), continue maturation and 
eventually leave the thymus. Finally, the effect of the transgenic integration site cannot be 
excluded to contribute to thymic abnormalities in the rOT-II+/+ strain. 
 
4.1.2.2 rOT-II+/+ CD8+ T CELLS INTERACT WITH MHC CLASS II 
T cells isolated from rOT-II+/+ lymph nodes reacted to the antigen ovalbumin in a MHC class 
II restricted manner, demonstrated by that fact that a blocking of MHC II by OX-6 antibody 
fully abolished T cell proliferation and cytokine production (Fig. 3.17). However, not only 
CD4+ but also CD8+ separated T cells reacted to ovalbumin in a dose-dependent manner 
(Fig. 3.18). Moreover, isolated CD8+ cells also were responsive to the OVA323-339 peptide 
which is selectively presented by MHCII complex (data not shown).  
Speculatively, rOT-II+/+ CD8+ T cells could be either true cytotoxic CD8 T cells which have 
undergone homeostatic proliferation in the periphery or misguided pseudo-CD8 T cells that 
failed to upregulate CD4 but nevertheless can exercise helper functions. The latter were 
previously reported in CD4-/- mice: In this setting, MHC class II restricted T cells develop 
into CD8+ T cells (Matechak et al., 1996). CD8 T cells were reported to be able to interact 
with MHC class II (Tyznik et al., 2004). In mice it was recently shown that a CD8-MHC II 
interaction is possible and important for shaping the proliferation and differentiation of CD8+ 
T cells (Do et al., 2012). 





4.2 EAE DEVELOPMENT IN TCR TRANSGENIC LEWIS RAT STRAINS 
TCR transgenic mice models with receptors specific for MBP, PLP or MOG did develop 
spontaneous EAE – depending on the mouse strain, housing conditions and antigen 
(Goverman et al., 1993; Lafaille et al., 1994; Bettelli et al., 2003; Pollinger et al., 2009). We 
observed rMT-II rats for more than one year and found neither signs of clinical symptoms 
nor any subclinical infiltrations of immune cells into the CNS of rMT-II rats. 
In MBP-TCRtg transgenic mouse strains it is also possible to induce EAE development by 
activating the innate immune system through injection of LPS (Goverman et al., 1993). To 
test whether our TCR transgenic rats might be susceptible to EAE induction by stimulation 
of Toll-like receptors, we injected LPS intrathecally with or without additional antigen 
directly targeting the integrity of the BBB and activating innate immune cells of the CNS. 
This treatment failed to induce clinical EAE. This indicates that the mere opening of the 
BBB and generation of a local proinflammatory environment are insufficient to trigger 
quiescent peripheral myelin-specific T cells to attack the CNS. Moreover, i.t. transfer of 
recently activated rMT-II+/+ T cells also failed to induce disease, showing that not only the 
access to CNS tissue but also some intrinsic properties of T cells presumably acquired 
during post-activatory maturation are critical for initiation of T cell mediated CNS 
inflammation.   
 
4.2.1 ACTIVE EAE INDUCTION IN TCR TRANSGENIC ANIMALS 
To analyse the impact of the MBP-specific and OVA-specific transgenic T cells on EAE 
development, we immunized heterozygous and homozygous rMT-II and rOT-II as well as 
wild type littermates with MBP in CFA. We observed a remarkably accelerated disease 
onset in rMT-II rats and a delayed onset and a reduced incidence of EAE in rOT-II rats. 
However, susceptible rOT-II rats developed EAE with a similar severity and progression as 
WT littermates (Fig. 3.19).    
As the majority of T cells in rMT-II rats expressed the transgenic V8.2 chain, the 
accelerated disease onset could be explained by a higher number of MBP-specific T cells 
in their immune repertoire. Upon immunization, T cells proliferate and migrate in higher 
numbers into the CNS where these cells become reactivated and cause severe 
inflammation. In contrast, WT rats host a smaller population of autoreactive T cells, which 
need longer to reach numbers after amplification, able to start a similar immune response 
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within the CNS. Concerning disease duration and severity, EAE in rMT-II rats resembled 
the disease course of WT littermates. This indicates a role for the TCR transgenic T cells 
only in disease initiation but not in maintenance and resolution of the inflammatory 
response in the target tissue.  
On the contrary, rOT-II rats possessed predominantly OVA-specific T cells which left only a 
minority of T cells with autoaggressive specificity. Therefore, we already observed a 
reduced incidence of EAE development in heterozygous rOT-II rats which was even more 
pronounced in homozygous rOT-II rats. However, in rOT-II rats which did develop EAE, the 
disease manifested itself with the same clinical course and disease severity as observed in 
WT littermates, also supporting the observation that the mere number of autoaggressive T 
cells is important for disease initiation. 
We additionally aimed to induce EAE with differential disease progressions. To this extent, 
rMT-II+/- rats were immunized a second time with MBP in CFA ten days after disease 
resolution. Here we could induce a second disease bout whereas WT littermates remained 
resistant as was previously reported (Sun et al., 1999). Interestingly, the treatment of 
immunized rMT-II+/+ rats with the calcineurin inhibitor FK506 during the prodromal phase 
resulted in a mild first clinical episode synchronized to EAE onset in the control group 
followed by short remission and a second, severe bout of paralysis which however 
eventually also resolved (Fig. 3.21). Taken together these results suggest that the absolute 
number of autoreactive T cells and induction of Treg response determine the initiation of 
EAE and acquired resistance to it. However, other factors, e.g. those preventing chronic 





4.3 MIGRATORY ROUTES AND ACTIVATION PATTERN OF NAÏVE AND 
EFFECTOR T CELLS 
4.3.1 rMT-II+/+ EFFECTOR T CELLS INDUCE SEVERE, RAPID AND ATYPICAL EAE 
For comparison of splenic antigen inexperienced T cells and effector T cells, we generated 
effector T cell lines derived from rMT-II+/+ and rOT-II+/+ hosts. In vitro analysis of surface 
markers and kinetics of mRNA expression showed similarities in transgenic effector T cells 
compared to conventional (polyclonal) effector T cell lines generated from WT animals 
(Fig. 3.25). Our conventional T cell lines are retrovirally engineered to express GFP  
(Flügel et al., 1999). Endogenous GFP expression in homozygous transgenic rats did not 
reach equal expression levels. Thus, we additionally transduced rMT-II+/+ effector T cells 
with our GFP retrovirus (termed GFPretro) to boost GFP expression levels (data not shown) 
and guarantee a better visualisation by the means of epifluorescence microscopy or two-
photon microscopy. 
When applied for adoptive transfer EAE, both rMT-II+/+ and GFPretro rMT-II+/+ effector T cells 
induced strong EAE with an onset already two days after transfer with not only typical 
ascending paralysis but also atypical neurological symptoms like partial tetraparesis, 
hyperaesthesia and tremor (Fig. 3.26). This prompted us to analyse the distribution of 
inflammatory infiltrates throughout the CNS. The number of infiltrating T cells into lumbal 
and cervical spinal cord did not differ significantly at the peak of the disease between  
rMT-II+/+ effector T cell-induced EAE and conventional TMBP-GFP-induced EAE. However, 
rMT-II+/+ effector T cells did infiltrate brain regions including the cerebellum, medulla and 
cerebrum as well. Additionally, we observed a stronger activation of microglia and 
recruitment of macrophages in regions where T cells infiltrated (Fig. 3.27).   
Taken together, rMT-II+/+ effector T cells induced fulminant EAE affecting both spinal cord 
and brain. Whether this infiltration pattern is an intrinsic feature of these T cell lines caused 
by their homogenous specificity for MBP or a higher basal activity enabling these cells to 
enter the CNS more rapidly remains to be investigated. Odoardi et al. recently reported that 
conventional TMBP-GFP effector T cells could not enter the CNS directly but have to migrate 
through the periphery to acquire a migratory phenotype (Odoardi et al., 2012). As the first 
rMT-II+/+ effector T cells were already detectable in the spinal cord 24 h after intravenous 
transfer and the disease onset was accelerated compared to conventional TMBP-GFP 
adoptive transfer EAE, it will be interesting to analyse the gene expression pattern and its 
kinetic in rMT-II+/+ effector T cells during the prodromal phase of EAE in more detail. 
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4.3.2 SPLENIC AND EFFECTOR rMT-II+/+ CELLS ACCELERATE EAE ONSET  
AFTER LOCAL ACTIVATION 
In rOT-II and rMT-II rats, GFP and TCR expression are under the control of the introduced 
ubiquitin C promoter leading to the expression of GFP in almost all cell types. Specifically 
for histology and two-photon live imaging, the GFP expression in all cell types is a limitation 
as endogenous GFP+ T cells cannot be easily distinguished from the GFP background 
signal. To circumvent this inconvenience, we established a transfer system with local 
activation of transferred T cells in the popliteal lymph node. In this system, transferred 
spleen-derived T cells or effector T cell lines migrate to the popliteal lymph node where 
they become activated by immunization (Fig. 3.30). Splenic rMT-II+/+ T cells proliferated 
locally and entered the blood circulation approximately 3-4 days post immunization before 
infiltrating CNS meninges and parenchyma 5-6 days post immunization causing an 
accelerated EAE onset (Fig. 3.28 and 3.30 A). Transfer of splenic rOT-II+/+ T cells in a 
control experiment resulted in a disease onset around day 10 after MBP-immunization. 
Interestingly, heterozygous rMT-II+/- transferred splenic T cells also caused an accelerated 
disease onset 8 days post immunization. Subcutaneous transfer of resting rMT-II+/+ effector 
T cells and subsequent immunization even further accelerated the disease onset (4 dpi, 
Fig. 3.28) and was accompanied by a rapid proliferation of T cells in the popliteal lymph 
nodes and infiltration into CNS meninges and parenchyma 4 dpi (Fig. 3.30 B). Notably, the 
absolute numbers of GFP+ T cells in the different organs for rMT-II+/+ effectors were 10 to 
200-fold lower than numbers of splenic rMT-II+/+ T cells. Presumably, differentiation into 
effector subset already allows a small number of T cells to enter the target organ and 
mount the immune response whereas splenic antigen inexperienced T cells need a longer 
period to expand to sufficient numbers and reach a sufficient activation/maturation state. 
We analyzed splenic and effector T cells in the CNS meninges and parenchyma for CD25 
surface expression, a marker for activation. Similar levels of CD25 were expressed on both 
types of T cells upon re-activation in the target tissue. However, the effector T cells showed 
a much higher basal expression of CD25 before transfer and during peripheral migration. 
This indicates that the effector phenotype predisposes T cells to a stronger activation by 
repeated antigen encounter than the splenic naïve/memory population. The higher 
responsiveness was also reflected at the mRNA level, as rMT-II+/+ effector T cells produced 
a 4-10-fold higher amount of the proinflammatory cytokines IFN, IL-17 and TNF in the 
CNS meninges and parenchyma during the disease onset (Fig. 3.31). 
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Collectively these data could show a capability of rMT-II-derived cells to accelerate the EAE 
onset. Effector T cells appeared in lower numbers in the periphery and the target tissue but 
inherited a stronger activation status manifested by increased production of 
proinflammatory cytokine mRNA. On the other hand, splenic antigen inexperienced T cells 
appeared in higher numbers. This might be due to the execution of a different migratory 
program, which could compensate a lower production of proinflammatory cytokines and 
result in a similar clinical disease. 
Additionally, the migratory route of T cells after local activation might follow a T cell intrinsic 
programme. Splenic rOT-II+/+ and rOT-II+/+ effector T cells expanded first within the popliteal 
lymph nodes and traffic via the blood circulation to other peripheral organs following a 
similar time schedule as rMT-II+/+ derived T cells, again with lower total numbers of effector 
T cells (Fig. 3.34). To confirm this observation, rOT-II+/+ T cells have to be characterized in 
detail in this experimental setup for surface molecule expression and gene regulation.  
 
4.3.3 SPLENIC AND EFFECTOR rMT-II+/+ T CELLS INFILTRATE THE CNS UTILIZING 
DIFFERENT SETS OF CHEMOKINE RECEPTORS 
We then aimed to compare the migratory behaviour of splenic rMT-II+/+ T cells and effector 
rMT-II+/+ T cells in the CNS meninges via two-photon live imaging (Fig. 3.32).  
In both settings we could observe a massive infiltration of GFP+ T cells in the CNS 
meninges before the onset of clinical symptoms. Notably, when analyzing the migratory 
phenotype of splenic rMT-II+/+ T cells, we could not observe any T cells crawling along the 
blood vessel endothelium before transmigrating into the CNS tissue. 
Transmigration of T cells across the blood-brain barrier is described as a four-step process. 
First, T cells roll along the blood vessel endothelium in the direction of the blood flow and 
adhere to the vessel endothelium via interaction with integrins (e.g. ICAM-1 and VCAM-1). 
This enables T cells to change their migratory phenotype and crawl along the blood vessel 
endothelium against the direction of the blood flow resulting in subsequent diapedesis. The 
crawling process can be mediated by chemokine receptor signalling as the chemokines 
CCL19 and CCL21 are upregulated in endothelial cells of the mouse CNS during EAE and 
CXCR3, a receptor capable of interacting with CCL21 (Alt et al., 2002), is expressed on 
effector T cells.  
A member of our group, Dr. C. Schläger, showed in his PhD thesis study that in Lewis rat 
EAE the crawling process is indeed dependent on CXCR3-mediated interactions with the 
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endothelium as intravenous injection of a monoclonal blocking CXCR3 abrogates crawling 
behaviour of T cells (Schläger, 2013). Although we observed crawling behaviour of effector 
rMT-II+/+ T cells shortly before entering the CNS we did not observe such crawling in splenic 
rMT-II+/+ T cells. For this reason we analyzed both types of T cell for their gene expression 
level of CXCR3, CCR2 and CCR5 and could show that effector T cells expressed higher 
levels of these chemokine receptors in cells sorted from blood before the disease onset 
(Fig. 3.33). Lower expression levels of CXCR3 and CCR5 might account for the absence of 
crawling behaviour in splenic rMT-II+/+ T cells. Nevertheless, splenic T cells were also able 
to cross the blood barrier and induce disease implying that other mechanism for 
transmigration must be involved for these T cells. Another chemokine receptor interacting 
with CCL19 and CCL21 is CCR7. mRNA levels of CCR7 were upregulated in splenic  
rMT-II+/+ T cells sorted from blood compared to effector rMT-II+/+ T cells hinting at differential 
roles in chemokine receptor – endothelium interaction for splenic and effector T cells.  
An analysis will be performed of chemokine receptor expression but also expression of 
integrins using molecular methods in combination with intravital imaging to further dissect 
the factors and mechanisms utilized by recently primed and by fully differentiated effector 
T cells to cross the blood-brain barrier. 
 
4.3.4 rMT-II+/+ SPLENIC T CELLS CAN DEVELOP INTO TCM T CELLS 
As we observed heterogenous T cell subpopulations in untreated rats concerning the 
CD62L-CCR7 coexpression, we followed the regulation of CD62L surface expression 
during the course of EAE after local activation. 
Interestingly, we could obtain a CD62L+ T cell subpopulation from blood during the disease 
onset in splenic rMT-II+/+ induced EAE but not in effector rMT-II+/+ T cell induced EAE 
Fig. 3.34). Gene expression analysis of GFP+ CD62L+ and GFP+ CD62L- splenic rMT-II+/+ 
T cells sorted from blood in comparison to endogenous CD62L+ or CD62L- T cells showed 
an upregulation of IFN and TNF mRNA as well as the expression of CCR7 but the lack of 
CCR2 or CCR5 mRNA expression identifying these cells as central-memory T cells 
(Sallusto et al., 1999; Zhang et al., 2010). As this T cell population was not present during 
effector rMT-II+/+ T cell induced EAE, we can conclude that some splenic rMT-II+/+ possess 
the capability to develop into central-memory T cells while this aptitude seems to be absent 
in effector T cells. 
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4.3.5 MIGRATORY PATTERN IS A T CELL INTRINSIC FEATURE 
As the migratory routes we observed for rMT-II+/+ T cells after subcutaneous transfer and 
activation might be a part of  T cell intrinsic migratory programme common for T cells of any 
specificity, we also analyzed rOT-II+/+ splenocytes and effector rOT-II+/+ T cells in the same 
experimental settings (Fig. 3.35).  
Interestingly, OVA-specific splenic and effector T cells followed a similar migratory route 
with first a massive expansion in the draining popliteal lymph node, migration into the blood 
and subsequent homing to other lymph nodes, spleen and lung. Moreover, splenic rOT-II+/+ 
T cells expressed lower mRNA levels of chemokine receptors necessary to home into 







Autoreactive T cells directed against CNS antigens seem to play an essential role at least in 
the initiation of multiple sclerosis. To improve our understanding about the function of 
pathogenic T cells in CNS autoimmunity we aimed to endow the classical 
neuroimmunlogical Lewis rat EAE model with new analytic power. To do this, we generated 
two TCR transgenic Lewis strains: the rMT-II strain carrying T cells specific for the self-
antigen myelin basic protein and the rOT-II strain in which the transgenic TCR is specific for 
chicken ovalbumin. To our knowledge, these are first available TCRtg models created in 
R. norvegicus.  
The immune system of the rMT-II+/+ strain is characterised by a high proportion of CD4+ 
MHC class II restricted T cells readily responding to MBP challenge by proliferating and 
producing proinflammatory cytokines.  Although no spontaneous EAE was observed in 
rMT-II rats, this strain is highly susceptible to an early-onset severe monophasic EAE 
induced by active immunization even with reduced amounts of adjuvant or antigen. 
Repeated immunization induced relapse EAE in rMT-II, but not in WT Lewis rats. Peripheral 
T cells isolated from rMT-II donors were able to mediate an accelerated onset of active EAE 
upon transfer into WT recipients. Remarkably, the effector T cell lines established from 
rMT-II rats were highly encephalitogenic and caused severe EAE including atypical 
symptoms with increased propensity to infiltrate not only the spinal cord but also brain 
tissue.  
In the rOT-II+/+ strain the majority of peripheral T cells express a transgenic TCR specific for 
ovalbumin. In this strain, however, thymic development is disturbed leading to moderate 
lymphopenia, aberrant expression of the CD8 coreceptor in mature OVA-reactive T cells 
and reduction of the CD62L+ population. Still, this line can be used to track priming and 
migration of non-pathogenic OVA-specific T cells upon adoptive transfer.  
A green fluorescent marker which is co-expressed with each transgenic TCR greatly 
facilitates phenotyping and analysis of T cell migration. Further, its high expression by 
endothelial and myeloid cells can be exploited to visualize interaction of meningeal BBB 
structures with invading immune cells by TPM using rOT-II animals as a host for transfer 
experiments.        
Using an experimental setup comprising adoptive transfer and local activation in the 
draining LN, we performed analysis of migration and gene expression of cytokines and 
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chemokine receptors in naïve and effector populations of MBP- and OVA-specific T cells 
in vivo. Furthermore, TPM analysis of rMT-II+/+ cells invading the spinal cord during EAE 
induced by peripheral T cell activation revealed differences in behaviour of primary versus 
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